ucsf helen diller family comprehensive...

American Society of Clinical Oncology Annual Meeting

UCSF HELEN DILLER FAMILY COMPREHENSIVE CANCER CENTER

June 3-7, 2016Chicago, ILUCSF Presentation Brochure

2

As president of the UCSF Helen Diller Family Comprehensive Cancer

Center, one of my key priorities is to initiate and advance programs

that are developing new anticancer drugs making significant impact

on helping cancer patients live longer and better lives. I recognize this

goal is best accomplished by working in partnership with the broader

life science industry. This searchable abstract book of UCSF research

presented at ASCO is a resource for potential partners interested in

identifying world-class faculty engaged in clinical oncology research.

As an NCI-designated comprehensive cancer center, UCSF is

recognized for our outstanding science, extensive resources, depth

and breadth of our research in basic, clinical, and/or population

sciences, as well as cutting edge research that bridges these

scientific areas. Practically this means that our clinicians and basic

scientists work closely together to (1) identify, develop and optimize

novel therapeutics for biological efficacy and clinical utility, (2) assess

tumor status and responsiveness to current therapies, (3) develop

biomarkers for patient stratification and therapeutic response and (4)

advance supportive care options to mitigate the toxicities associated

with chemotherapy.

As is evident from the breadth and depth the research being

presented at this year’s ASCO, UCSF is home to many of world’s

finest oncology scientists and clinicians. I invite you learn more about

our work and expertise by reaching out to our faculty. If you have any

additional questions or need any assistance with your outreach, please

contact the Director of Strategic Alliances for the Cancer Center:

Cammie Edwards ( ).

Wishing you a very productive meeting and we look forward to

future discussions and collaborations.

Alan Ashworth, PhD, FRSPresident, UCSF Helen Diller Family Comprehensive Cancer Center

Committed to Advancing Development of Improved Cancer Therapies, Imaging Modalities, and Biomarkers

Alan Ashworth, PhD, FRSPresident, UCSF Helen Diller Family Comprehensive Cancer Center

Senior Vice President for Cancer Services, UCSF Health

Professor of Medicine, Division of Hematology/Oncology, Department of Medicine

3

The “comprehensive” designation—NCI’s highest ranking, awarded only after a rigorous evaluation process—recognizes UCSF’s excellence in basic research, clinical research, population based research, outreach and education, and our ability to integrate these diverse research approaches to cancer and turn them into clinical practice.

A Designated NCI Comprehensive Cancer Center Since 1999

HDFCCC Overview

Our Success is Driven by Our FacultyHDFCCC Membership: 397 Members & Associate Members2 Nobel Laureates

3 Albert Lasker Award winners

8 Howard Hughes Medical Investigators

13 Members of the National Academy of Sciences

20 Members of the Institute of Medicine

18 Fellows of the American Academy of Arts and Sciences

4 Fellows of the Royal Society

Working Together Advancing the Understanding and Treatment of Cancer

HDFCCC Overview

Advancing the Next Wave of Cancer Treatment BreakthroughsWhether it is pioneering novel clinical trial designs, discovering, developing and bringing to the clinic revolutionary treatments such as immunotherapies or harnessing the power of big data to drive faster, personalized and more effective cures, UCSF leads in advancing the next wave of cancer treatment breakthroughs. With a culture of collaboration, a commitment to excellence and access to cutting-edge laboratory and clinical technologies, UCSF faculty work tirelessly to improve clinical outcomes for cancer patients everywhere.

Multi-Disciplinary Research Programs• Breast Oncology

• Cancer Control

• Cancer Genetics

• Cancer, Immunity, and Microenvironment

• Developmental Therapeutics

• Hematopoietic Malignancies

• Neurologic Oncology

• Pediatric Malignancies

• Prostate Cancer

• Tobacco Control

Key Initiatives• Cancer Imaging

• Cancer Immunotherapeutics

• Global Oncology

• Center for BRCA Research

• UCSF 500

• Target Validation Initiative

Multi-Disciplinary Clinical Programs • GU Oncology (non Prostate)

• GI (includes Pancreas Cancer)

• Thoracic Oncology

• Cutaneous Oncology

• Head and Neck Cancer

• Sarcoma

• Endocrine

• Gynecologic Oncology

• Breast Oncology

• Prostate Cancer

5

• Biostatistics

• Clinical Research Support

• Genome Analysis

• Laboratory for Cell Analysis

• Immunohistochemistry & Molecular Pathology

• Mouse Pathology

• Preclinical Therapeutic Testing

• Bio-specimen Banking

• Tobacco Biomarkers

• Bioinformatics

• Computational Biology

UCSF consistently ranks among

the top U.S. biomedical research

organizations in cancer-specific

federal funding. In 2015, UCSF

received more than $85M from the

National Cancer Institute.

HDFCCC Overview

Core Capabilities Supporting Our Programs

Approximately one-quarter of the

University’s ~2,200 full-time faculty

members work in cancer research or

cancer care.

UCSF faculty have a long history of working with industry partners translating discoveries into products that ultimately improve patient care. We are experienced in establishing and executing on a wide range of successful partnerships. If you are interested in learning more about working with the HDFCCC and its faculty, please contact:

Cammie Edwards, PhDDirector of Strategic Alliances, HDFCCC

• On average, UCSF has 200-300 new invention disclosures per year

• An estimated 90 life science start-up companies have been spawned from the University’s labs, including Genentech, Chiron, and Intellikine

• Included among UCSF patents are top revenue producers, such as

UCSF IN THE NEWS (Click on title to read story)

Partnering with UCSF HDFCCC

New Cancer Immunotherapy Clinic Offers Unique Studies of Promising Treatmentshttps://www.ucsf.edu/news/2016/04/402411/new-cancer-immunotherapy-clinic-offers-unique-studies-promising-treatments

New UCSF Center for BRCA Research Expands Care for Increased Cancer Riskhttp://cancer.ucsf.edu/news/2016/04/19/new-ucsf-center-for-brca-research-expands-care-for-increased-cancer-risk.7470

Better Survival for Colon Cancer Patients with Left-Sided TumorsLocation Matters, Says Study to Be Presented at ASCOhttp://cancer.ucsf.edu/news/2016/05/18/better-survival-for-colon-cancer-patients-with-left-sided-tumors.7638

Berger, Bluestone Named to White House Cancer Moonshot Expert Panelhttp://cancer.ucsf.edu/news/2016/04/06/berger-bluestone-named-to-white-house-cancer-moonshot-expert-panel.7418

Read interview with UCSF’s Dr. Michael Korn on “When to Suspect Germline Abnormality from Genetic Testing Results” - ASCO daily news [ http://am.asco.org/dn ] | print version: June 6, 2016

- Hepatitis B vaccine

- Bovine growth hormone

- Barrier repair lipids

- Yeast expression vector

- Magnetic resonance imaging

https://www.ucsf.edu/news/2016/04/402411/new-cancer-immunotherapy-clinic-offers-unique-studies-promising-treatments

http://cancer.ucsf.edu/news/2016/04/19/new-ucsf-center-for-brca-research-expands-care-for-increased-cancer-risk.7470

http://cancer.ucsf.edu/news/2016/05/18/better-survival-for-colon-cancer-patients-with-left-sided-tumors.7638

http://cancer.ucsf.edu/news/2016/04/06/berger-bluestone-named-to-white-house-cancer-moonshot-expert-panel.7418

http://am.asco.org/dn

7

Presentations

*UCSF authors in bold

Presentations

Updated data from a phase II dose finding trial of single agent isatuximab (SAR650984, anti-CD38 mAb) in relapsed/refractory multiple myeloma (RRMM).

Authors*: Joshua Ryan Richter, Thomas G. Martin, Ravi Vij, Craig Cole, Djordje Atanackovic, Jeffrey A. Zonder, Jonathan L. Kaufman, Joseph Mikhael, William Bensinger, Meletios A. Dimopoulos, Todd M. Zimmerman, Nikoletta Lendvai, Parameswaran Hari, Enrique M. Ocio, Cristina Gasparetto, Shaji Kumar, Corina Oprea, Eric Charpentier, Stephen Anthony Strickland, Jesus San Miguel

Abstract #: 8005

Presentation Date/Time: Friday, June 3: 3:00 - 6:00 PM

Location: E354b Session: Hematologic Malignancies - Plasma Cell DyscrasiasCitation: J Clin Oncol 34, 2016 (suppl; abstr 8005)

Martin Research Interests: A leading expert in hematology-oncology, Dr. Thomas Martin is the associate director of the Myeloma Institute and director of the Unrelated Donor Transplantation Program for adults at UCSF Medical Center. He is also the clinical research directory of hematologic malignancies, or blood cancers, at the UCSF Helen Diller Family Comprehensive Cancer Center. His research interests include developing treatments for myeloma and leukemia as well as expanding the use of bone marrow transplants. He has a special interest in umbilical cord blood transplants and is involved in efforts to improve the outcomes following unrelated donor transplants.

http://cancer.ucsf.edu/research/multiple-myeloma/mmti/mmti_team#martin

View full abstracts on line at: http://am.asco.org/abstracts


http://am.asco.org/abstracts

http://www.abstractsonline.com/plan/start.aspx?mkey=%7b1D10D749-4B6A-4AB3-BCD4-F80FB1922267%7d

8

Presentations


Plasma asparaginase activity and asparagine depletion in patients with acute lymphoblastic leukemia (ALL) treated with pegaspargase (SS-PEGE. coli L-asparaginase): Results from Children’s Oncology Group (COG) study AALL07P4.

Authors*: Reuven J. Schore, Meenakshi Devidas, Archie Bleyer, Gregory H. Reaman, Naomi J. Winick, Mignon L. Loh, Elizabeth A. Raetz, William L. Carroll, Stephen Hunger, Anne L. Angiolillo

Abstract #: 10508


Location: S504

Session: Pediatric Oncology I

Citation: J Clin Oncol 34, 2016 (suppl; abstr 10508) __________________________________________________________________________

MONARCH1: Results from a phase II study of abemaciclib, a CDK4 and CDK6 inhibitor, as monotherapy, in patients with HR+/HER2- breast cancer, after chemotherapy for advanced disease.

Authors*: Maura N. Dickler, Sara M. Tolaney, Hope S. Rugo, Javier Cortes, Véronique Diéras, Debra A. Patt, Hans Wildiers, Martin Frenzel, Andrew Koustenis, Jose Baselga

Abstract #: 510


Location: Hall D1

Session: Future Directions in Breast Cancer Treatment: New Drugs, New Markers

Citation: J Clin Oncol 34, 2016 (suppl; abstr 510)

Rugo Research Interests: Dr. Rugo, Director of Breast Oncology & Clinical Trials Education, is PI on multiple clinical trials focusing on combining novel targeted therapeutics to improve the treatment of both early & late stage breast cancer (BC). She also works on studies to improve supportive care for early & late stage BC patients, including with UCSF’s Advanced Breast Cancer Program. Dr. Rugo has numerous collaborations with large academic medical centers & consortia in order to expand the novel therapies available to patients. She was the director of the 2016 ASCO Breast Cancer Education Committee meeting, is a member of the Alliance & is a founding member of the Breast Cancer Research Consortium where she co-leads the triple negative working group. She is on the novel agents committee for the neoadjuvant multi-center I SPY2 trial. At UCSF, Dr. Rugo runs the Breast Forum, a bimonthly educational session for breast cancer patients, families & friends from throughout the bay area.

http://cancer.ucsf.edu/people/profiles/rugo_hope.3648

9

Presentations


Phase II trials of cetuximab plus combined modality therapy (CMT) in squamous cell carcinoma of the anal canal (SCCAC) with and without human immunodeficiency virus (HIV) infection.

Authors*: Madhur Garg, Fengmin Zhao, Jeannette Y. Lee, Joseph A. Sparano, Joel Palefsky, David H. Henry, William Wachsman, Lakshmi Rajdev, David Michael Aboulafia, Lee Ratner, Lisa A. Kachnic, Edith P. Mitchell, Adedayo A. Onitilo, Ronald T. Mitsuyasu, Al Bowen Benson

Abstract #: 3522

Presentation Date/Time: Saturday, June 4: 8:00 - 11:30 AM

Location: Hall A Poster Board # 219

Session: Gastrointestinal (Colorectal) Cancer


Blood-based biomarkers in patients (pts) with metastatic colorectal cancer (mCRC) treated with FOLFOX or FOLFIRI plus bevacizumab (Bev), cetuximab (Cetux), or bev plus Cetux: Results from CALGB 80405 (Alliance).

Authors*: Andrew B. Nixon, Alexander Sibley, Ace Joseph Hatch, Yingmiao Liu, Chen Jiang, Flora Mulkey, Mark D. Starr, John C. Brady, Donna Niedzwiecki, Federico Innocenti, Alan P. Venook, Howard S. Hochster, Heinz-Josef Lenz, Bert H. O’Neil, Kouros Owzar, Herbert Hurwitz

Abstract #: 3597


Location: Hall A, Poster Board #294



Venook Research Interests: Dr. Alan Venook is a nationally renowned expert in colorectal and liver cancers at the UCSF Helen Diller Family Comprehensive Cancer Center. He is highly regarded for his expertise in the effective use of the newest approaches and therapies to the treatment of colorectal cancer, as well treating primary and metastatic tumors to the liver. Dr. Venook has chaired and/or authored six major studies within the cooperative groups and he now Chairs the GI Committee of the Alliance for Clinical Trials in Oncology (formerly CALGB.)

http://cancer.ucsf.edu/people/profiles/venook_alan.3698

10

Presentations


A phase 2 study of galunisertib, a novel transforming growth factor-beta (TGF-β) receptor I kinase inhibitor, in patients with advanced hepatocellular carcinoma (HCC) and low serum alpha fetoprotein (AFP).

Authors*: Sandrine J. Faivre, Armando Santoro, Edward Gane, Robin Kate Kelley, I Ollivier Hourmand, Eric Assenat, Ivelina Gueorguieva, Ann Cleverly, Durisala Desaiah, Michael M. F. Lahn, Eric Raymond, Karim A. Benhadji, Gianluigi Giannelli

Abstract #: 4070



Session: Gastrointestinal (Noncolorectal) Cancer


A randomized, double-blinded, placebo-controlled phase II trial of gemcitabine (gem) plus nab-paclitaxel (nab-P) plus apatorsen (A) or placebo (Pl) in patients (pts) with metastatic pancreatic cancer (mPC): The RAINIER trial.

Authors*: Andrew H. Ko, Patrick Brian Murphy, James D. Peyton, Dianna Shipley, Ahmed Al-Hazzouri, Francisco Antonio Rodriguez, Mark Sanders Womack, Henry Q. Xiong, David Michael Waterhouse, Margaret A. Tempero, Shuangli Guo, Cassie Michelle Lane, Christopher Earwood, Laura M. DeBusk, Johanna C. Bendell

Abstract #: 4119



Poster Session: Gastrointestinal (Noncolorectal) Cancer


Ko Research Interests: My work focuses on gastrointestinal malignancies, where I have developed and led multiple clinical trials, both within UCSF and across multiple sites. I am interested in the development and evaluation of new therapeutic agents ranging from novel cytotoxics to molecular targeted agents to immunotherapies, with a particular emphasis in pancreatic cancer. This work entails collaborating with laboratory-based investigators on translational science to identify individual patient/tumor characteristics that influence prognosis and response to specific therapies. I lead the UCSF site committee for gastrointestinal cancer-specific clinical trial development and serve as chair of the scientific Protocol Review Committee. Nationally, I sit on the editorial board for multiple peer-reviewed oncology journals, am a member of NCI’s Pancreatic Cancer Task Force and the NCCN Pancreatic Cancer guidelines committee.

http://cancer.ucsf.edu/people/profiles/ko_andrew.3444

11

Presentations


CRS-207 immunotherapy expressing mesothelin, combined with chemotherapy as treatment for malignant pleural mesothelioma (MPM).

Authors*: Raffit Hassan, Evan W. Alley, Hedy L. Kindler, Scott Joseph Antonia, Thierry Marie Jahan, Somayeh Honarmand, Katherine McDougall, Chan C. Whiting, Nitya Nair, Amanda Enstrom, Ed Lemmens, Takahiro Tsujikawa, Sushil Kumar, Lisa M Coussens, Aimee Murphy, Anish Thomas, Dirk G. Brockstedt

Abstract #: 8558



Session: Lung Cancer - Non-Small Cell Local-Regional/Small Cell/Other Thoracic Cancers


Pembrolizumab (pembro) plus chemotherapy as front-line therapy for advanced NSCLC: KEYNOTE-021 cohorts A-C.

Authors*: Shirish M. Gadgeel, James Stevenson, Corey J. Langer, Leena Gandhi, Hossein Borghaei, Amita Patnaik, Liza Cosca Villaruz, Matthew A. Gubens, Ralph J. Hauke, James Chih-Hsin Yang, Lecia V. Sequist, Robert D. Bachman, Joy Yang Ge, Harry Raftopoulos, Vassiliki Papadimitrakopoulou

Abstract #: 9016



Session: Lung Cancer - Non-Small Cell Metastatic


Gubens Research Interests: Matthew Gubens is a thoracic oncologist who treats patients with lung cancer, mesothelioma and other thoracic malignancies, including thymoma and thymic carcinoma, which are rare tumors of the mediastinum. His research involves designing clinical trials to study new compounds and treatment strategies in lung cancer. He and his colleagues have a special interest in translational medicine, and are actively working to translate laboratory-based findings to the clinic, especially for patients with epidermal growth factor receptor (EGFR) mutations. The group is also active in trials evaluating new immunotherapy approaches in thoracic malignancies. Dr. Gubens is a member of the American Society of Clinical Oncology, the International Association for the Study of Lung Cancer and the International Thymic Malignancy Interest Group.

http://profiles.ucsf.edu/matthew.gubens

12

Presentations


Pembrolizumab vs docetaxel for previously treated advanced NSCLC with a PD-L1 tumor proportion score (TPS) 1%-49%: Results from KEYNOTE-010.

Authors*: Edward B. Garon, Roy S. Herbst, Dong-Wan Kim, Enriqueta Felip, Jose Luis Perez-Gracia, Ji-Youn Han, Julian R. Molina, Joo-Hang Kim, Catherine Dubos Arvis, Myung-Ju Ahn, Margarita Majem, Mary J. Fidler, Matthew A. Gubens, Gilberto Castro, Marcelo Garrido, Yue Shentu, Ellie Im, Gregory M. Lubiniecki, Paul Baas

Abstract #: 9024







13

Presentations


Long-term OS for patients with advanced NSCLC enrolled in the KEYNOTE-001 study of pembrolizumab (pembro).

Authors*: Rina Hui, Leena Gandhi, Enric Carcereny Costa, Enriqueta Felip, Myung-Ju Ahn, Joseph Paul Eder, Ani Sarkis Balmanoukian, Natasha B. Leighl, Charu Aggarwal, Leora Horn, Amita Patnaik, Gary William Middleton, Matthew A. Gubens, Matthew David Hellmann, Jean-Charles Soria, Suresh S. Ramalingam, Gregory M. Lubiniecki, Jin Zhang, Bilal Piperdi, Edward B. Garon

Abstract #: 9026







14

Presentations


Phase I/II study of pembrolizumab (pembro) plus ipilimumab (ipi) as second-line therapy for NSCLC: KEYNOTE-021 cohorts D and H.

Authors*: Matthew A. Gubens, Lecia V. Sequist, James Stevenson, Steven Francis Powell, Liza Cosca Villaruz, Shirish M. Gadgeel, Corey J. Langer, Amita Patnaik, Hossein Borghaei, Shadia Ibrahim Jalal, Joseph Fiore, Joy Yang Ge, Harry Raftopoulos, Leena Gandhi

Abstract #: 9027



Poster Session: Lung Cancer - Non-Small Cell Metastatic




15

Presentations


Randomized phase 2 study of the safety, efficacy, and immune response of GVAX pancreas (with cyclophosphamide) and CRS-207 with or without nivolumab in patients with previously treated metastatic pancreatic adenocarcinoma (STELLAR).

Authors*: Dung T. Le, Todd S. Crocenzi, Jennifer N. Uram, Eric R. Lutz, Daniel A. Laheru, Elizabeth A. Sugar, Robert H. Vonderheide, George A. Fisher, Andrew H. Ko, Aimee Murphy, Katherine McDougall, Sandy Ferber, Dirk G. Brockstedt, Elizabeth M. Jaffee

Abstract #: TPS4153


Location: Hall A, Poster Board #134a


Citation: J Clin Oncol 34, 2016 (suppl; abstr TPS4153)


http://cancer.ucsf.edu/people/profiles/ko_andrew.3444

16

Presentations


Amethyst NSCLC trial: Phase 2, parallel-arm study of receptor tyrosine kinase (RTK) inhibitor, MGCD265, in patients (pts) with advanced or metastatic non-small cell lung cancer (NSCLC) with activating genetic alterations in mesenchymal-epithelial transition factor (MET).

Authors*: Igor I. Rybkin, Ebenezer A. Kio, Ashiq Masood, Merrill Kingman Shum, Balazs Halmos, Collin M. Blakely, Keith D. Eaton, Neelesh Sharma, John J. Nemunaitis, Steven J. Saccaro, Yanis Boumber, Raul R. Mena, Hamid R. Mirshahidi, Pasi A. Janne, James Christensen, Richard C. Chao, Vanessa Roberts Tassell, Demiana Faltaos, Marshall T. Schreeder

Abstract #: TPS9099




Citation: J Clin Oncol 34, 2016 (suppl; abstr TPS9099) __________________________________________________________________________

TIGER-3: A phase 3 multinational open-label randomized study of rociletinib vs investigator-choice chemotherapy in patients (pts) with epidermal growth factor receptor mutant-positive (EGFRm) non-small cell lung cancer (NSCLC) progressing on prior EGFR tyrosine kinase inhibitor (TKI) therapy and doublet chemotherapy.

Authors*: James Chih-Hsin Yang, Sanjay Popat, Silvia Novello, Harry J.M. Groen, Maurice Perol, Enriqueta Felip, Frank Griesinger, Karen L. Reckamp, Jong-Seok Lee, Egbert F. Smit, Collin M. Blakely, Wallace L. Akerley, Young-Chul Kim, Lyudmila Bazhenova, Raffaele Califano, Richard Delmar Hall, Panayiotis Georgiou, Jeffrey D. Isaacson, Tony Golsorkhi, Heather A. Wakelee

Abstract #: TPS9106


Location: Hall A, Poster Board 425b



17

Presentations


Genomic Profiling to distinguish poorly differentiated neuroendocrine carcinomas arising in different sites.

Authors*: Emily K. Bergsland, Ritu Roy, Phil Stephens, Jeffrey S. Ross, Mark Bailey, Adam Olshen

Abstract #: 4020



Poster Session: Gastrointestinal (Noncolorectal) Cancer


Bergsland Research Interests: My research is focused on the development and testing of novel, biologically based therapies for gastrointestinal malignancies, with an emphasis on neuroendocrine tumors (NETs). I am co-chair of the Neuroendocrine Tumor Task Force of the NCI Gastrointestinal Steering Committee, a NCCN Neuroendocrine Tumors Guidelines Panel member, Board of Directors member for NANETS, and co-chair of the 8th edition AJCC Expert Panel on staging for NETs. I am study chair for ALLIANCE A021202 (an ongoing randomized Phase II trial of pazopanib vs. placebo in patients with progressive carcinoid tumors). My current research focuses on data from three completed investigator-initiated Phase II clinical trials in NETs (a. FOLFOX/bevacizumab, b. everolimus plus erlotinib, and c. axitinib), fostering several collaborations with laboratory-based colleagues, and taking advantage of a fully annotated outcomes database (established in 2010 and encompassing 600+ NET patients treated at UCSF since 2004).

http://cancer.ucsf.edu/gi/emily-bergsland __________________________________________________________________________

Head and Neck Cancer Updates from the American Society for Radiation Oncology

Authors*: Sue Sun Yom

Abstract #:


Location: S100bc

Education Session: Best of the Rest: Top Abstracts on Head and Neck Cancer from the 2015-2016 Oncology Meetings

Citation:

Yom Research Interests: Dr. Yom is an expert in head and neck, thoracic, and skin cancers and conducts research in quality of life and supportive care, patient-oriented decision making, and combinations of novel targeted therapies and immunotherapy with radiation therapy. She is the principal investigator of HN002, a national trial in de-intensified therapy for HPV+ oropharyngeal cancer. She serves on several national panels developing guidelines for appropriate care of head and neck cancers.

http://profiles.ucsf.edu/sue.yom

18

Presentations


Comprehensive mutation analysis in NRG Oncology/RTOG 9813: A phase III trial of RT + TMZ vs RT + nu for anaplastic astrocytoma and mixed anaplastic oligoastrocytoma (Astrocytoma Dominant).

Authors*: Erica Hlavin Bell, Joseph P McElroy, Jessica Fleming, Cynthia Dawn Timmers, Arup R Chakraborty, Andrea L Salavaggione, Susan Marina Chang, Kenneth D. Aldape, David Brachman, Helen Alice Shih, Peixin Zhang, Minesh P. Mehta, Arnab Chakravarti

Abstract #: 2016

Presentation Date/Time: Saturday, June 4: 1:00 - 4:30 PM

Location: Hall A, Poster Board # 205

Session: Central Nervous System Tumors


Chang Research Interests: My research interest is in the development of novel therapies for patients with brain tumors, as well as the assessment of novel imaging biomarkers in the management of patients. My research seeks to integrate advances in physiologic and metabolic imaging with tissue biomarkers in order to optimize the management of patients with glioblastoma (GBM). My clinical research evaluates a wide spectrum of therapeutic interventions that span chemotherapy, targeted agents, immunotherapy and convection enhanced delivery of novel agents. I am the site PI of an NIH-funded adult brain tumor consortium and am a member of the Brain Malignancy Steering Committee and the Developmental Therapeutics Study Section at the NIH. I am the program leader for the Neuro-Oncology Program at the HDFCCC. I am the clinical co-PI for the UCSF Brain Tumor SPORE and a co-Leader of a SPORE Project evaluating the role of physiologic imaging in the determination of malignant progression of low-grade glioma.

http://cancer.ucsf.edu/people/profiles/chang_susan.3565

19

Presentations


Validating RNAseq-signatures of vorinostat (VOR) sensitivity and resistance in patients with newly diagnosed glioblastoma (GBM) treated with VOR, temozolomide and radiation therapy in Alliance N0874/ABTC-0902.

Authors*: S. Keith Anderson, C. Ryan Miller, Jann Nagina Sarkaria, Kurt A. Jaeckle, Jan C. Buckner, Keith L. Ligon, Karla V. Ballman, Dennis Frederic Moore, David Schiff, Manmeet Singh Ahluwalia, Eudocia Quant Lee, Laura E. Horvath, Elizabeth Robins Gerstner, Glenn Jay Lesser, Michael Prados, Stuart A. Grossman, Caterina Giannini, Patrick Y. Wen, Evanthia Galanis

Abstract #: 2029





Prados Research Interests: Dr. Prados is a world-recognized Neuro-oncology expert. He led the Adult Brain Tumor Consortium for over 15 years and founded the Pacific Pediatric Neuro-Oncology Consortium (PNOC), a multi-institutional consortium of now 15 major academic centers across the United States. Currently Dr. Prados is Professor Emeritus at UCSF devoting his efforts towards pediatric Neuro-Oncology clinical and translational research. He is the co-Project Leader of a pediatric brain tumor SPORE project at UCSF and is co-Project Leader of the PNOC. His major interests are early phase clinical trials research and the translational studies that precede and inform those trials in both adults and children. He is part of the Editorial board of Neuro-Oncology, Journal of Neuro-Oncology and Journal of Clinical Oncology, and a member of the NCI/CTEP Brain Malignancies Steering Committee. In 2014 he was awarded the Victor Levin Award for lifetime clinical research excellence from the Society of Neuro-Oncology.

http://cancer.ucsf.edu/people/profiles/prados_michael.3603 __________________________________________________________________________

Encouraging survival with Toca 511 and Toca FC compared to external lomustine control.

Authors*: Timothy Francis Cloughesy, Manish K. Aghi, Clark Chen, J. Bradley Elder, Santosh Kesari,Steven N. Kalkanis, George Kaptain, Joseph C. Landolfi, Tom Mikkelsen, Jana Portnow, Joan M. Robbins, Derek Ostertag, Asha Das, Alice Chu, Michael A. Vogelbaum

Abstract #: 2030



Poster Session: Central Nervous System Tumors


20

Presentations


Precision Medicine in recurrent glioblastoma: A feasibility trial conducted by the Ivy Foundation Early Phase Clinical Trials Consortium.

Authors*: Michael Prados, John G. Kuhn, Howard Colman, Timothy Francis Cloughesy, Susan Marina Chang, Nicholas A. Butowski, John Frederick De Groot, Patrick Y. Wen, Keith L. Ligon, Ingo K. Mellinghoff, Andrew S. Chi, Joanna J Phillips, Annette M Molinaro, Rebecca Halperin, Nhan Tran, Michael E. Berens, John D. Carpten, David W. Craig, Sara A. Byron

Abstract #: 2031



Poster Session: Central Nervous System Tumors


Prados Research Interests: Dr. Prados is a world-recognized Neuro-oncology expert. He led the Adult Brain Tumor Consortium for over 15 years and founded the Pacific Pediatric Neuro-Oncology Consortium (PNOC), a multi-institutional consortium of now 15 major academic centers across the United States. Currently Dr. Prados is Professor Emeritus at UCSF devoting his efforts towards pediatric Neuro-Oncology clinical and translational research. He is the co-Project Leader of a pediatric brain tumor SPORE project at UCSF and is co-Project Leader of the PNOC. His major interests are early phase clinical trials research and the translational studies that precede and inform those trials in both adults and children. He is part of the Editorial board of Neuro-Oncology, Journal of Neuro-Oncology and Journal of Clinical Oncology, and a member of the NCI/CTEP Brain Malignancies Steering Committee. In 2014 he was awarded the Victor Levin Award for lifetime clinical research excellence from the Society of Neuro-Oncology.

http://cancer.ucsf.edu/people/profiles/prados_michael.3603

21

Presentations


Phase I/II study of VAL-083 in patients with recurrent glioblastoma.

Authors*: Kent C. Shih, Manish R. Patel, Nicholas A. Butowski, Gerald Steven Falchook, Sani Haider Kizilbash, Jeffrey A. Bacha, Dennis Brown, Anne Steino, Richard Stephen Schwartz, Sarath Kanekal, Lorena Lopez, Howard A. Burris

Abstract #: 2063





Butowski Research Interests: My research includes translational research and a wide range of clinical trials, including those with convection-enhanced delivery (CED) with real-time MRI imaging, targeted agents, immunotherapy, and combination strategies. I am the Director of Translational Research in Neuro-Oncology and lead the translational effort on behalf of the UCSF Brain Tumor Research Center and Preclinical Core. My work has helped to create the groundwork for allied research in neuro-oncology and an extensive UCSF clinical trial portfolio for patients with primary brain and spine tumors, including an assortment of immunotherapy trials and surgically based trials. I have also designed investigator initiated trials, including a clinical trial employing intratumoral delivery with real-time MRI imaging as well as those with a range of novel targets, molecular markers and imaging biomarkers. I have also authored a number of peer-reviewed papers and presented work at national and international meetings.

https://www.ucsfhealth.org/nicholas.butowski

22

Presentations


Pilot study of T cells redirected to EGFRvIII with a chimeric antigen receptor in patients with EGFRvIII+ glioblastoma.

Authors*: Donald M. O’Rourke, MacLean Nasrallah, Jennifer J. Morrissette, Jan J. Melenhorst, Simon F. Lacey, Keith Mansfield, Maria Martinez-Lage, Arati Suvas Desai, Steven Brem, Eileen Maloney, Suyash Mohan, Sumei Wang, Gaurav Verma, Jean-Marc Navenot, Angela Shen, Zhaohui Zheng, Bruce Levine, Hideho Okada, Carl H. June, Marcela Valderrama Maus

Abstract #: 2067





Okada Research Interests: As a translational physician scientist, Dr. Okada and his lab are focused on development of novel immunotherapeutic strategies for brain tumor patients. For example, Dr. Okada conducted one of the first immune gene therapy trials in patients with malignant glioma. His lab was also the first to identify and fully characterized cytotoxic T-lymphocyte epitopes for gliomas. Dr. Okada has also delineated the role of an integrin receptor very late activation antigen-4 and chemokine CXCL10 in efficient trafficking of T-cells to brain tumor sites. Dr. Okada has integrated these findings to develop a number of vaccine trials in both adult and pediatric glioma patients. More recently, his group developed a novel chimeric antigen receptor targeting glioblastoma cells, and are currently conducting a pilot trial.

http://neurosurgery.ucsf.edu/index.php/about_us_faculty_okada.html

23

Presentations


Clinical and genomic characterization of metastatic small cell/neuroendocrine prostate cancer (SCNC) and intermediate atypical prostate cancer (IAC): Results from the SU2C/PCF/AARCWest Coast Prostate Cancer Dream Team (WCDT).

Authors*: Eric Jay Small, Rahul Raj Aggarwal, Jiaoti Huang, Artem Sokolov, Li Zhang, Joshi J. Alumkal, Jack Youngren, Charles J. Ryan, Adam Foye, Robert Evan Reiter, Christopher P. Evans, Martin Gleave, Owen Witte, Josh Stuart, Theodore C. Goldstein, George V. Thomas, Lawrence D. True, Himisha Beltran, Mark A. Rubin, Tomasz M. Beer

Abstract #: 5019



Poster Session: Genitourinary (Prostate) Cancer


Small Research Interests: The Stand Up To Cancer Dream Team led by Dr. Eric Small is exploring the idea that resistance to hormonal therapy occurs as a result of the prostate cancer cells using common cellular responses - what the Dream Team calls “adaptive pathways” - to escape the current prostate cancer therapies. They believe that, by identifying these pathways and inhibiting them, they will be able to overcome treatment resistance and profoundly improve the care of men affected by this fatal disease. This team is a six institution consortium to include UC Los Angeles, UC Davis, UC Santa Cruz, University of British Columbia, Oregon Health and Sciences University, with UCSF as the lead administrative site.

http://cancer.ucsf.edu/people/profiles/small_eric.3671 __________________________________________________________________________

Characteristics and anticancer interventions (ACIs) in African American (AA) and Caucasian (CAU) patients (pts) treated with sipuleucel-T (sip-T): Real-world experience from the PROCEED registry.

Authors*: Andrew J. Armstrong, Celestia S. Higano, Matthew R. Cooperberg, Chiledum Ahaghotu, Ronald F. Tutrone, Laurence H. Belkoff, Carl A. Olsson, Sanjay Goel, Robert Claude Tyler, Nancy N. Chang, Jennifer Susan LIll, A. Oliver Sartor

Abstract #: 5025



Session: Genitourinary (Prostate) Cancer


24

Presentations


Persistence of AR signaling in small cell neuroendocrine prostate cancer (SCNC) and intermediate atypical carcinoma (IAC): Results from the SU2C/PCF/AACR West Coast Prostate Cancer Dream Team (WCDT).

Authors*: Rahul Raj Aggarwal, Jack Youngren, Artem Sokolov, Jiaoti Huang, George V. Thomas, Lawrence D. True, Adam Foye, Joshi J. Alumkal, Charles J. Ryan, Tomasz M. Beer, Christopher P. Evans, Martin Gleave, Matthew Rettig, Joshua M. Stuart, Primo Lara, Theodore C. Goldstein, Li Zhang, Robert Evan Reiter, Kim N. Chi, Eric Jay Small

Abstract #: 5045






http://cancer.ucsf.edu/people/profiles/small_eric.3671

25

Presentations


IMAAGEN trial safety and efficacy update: Effect of abiraterone acetate and low-dose prednisone on prostate-specific antigen and radiographic disease progression in patients with nonmetastatic castration-resistant prostate cancer.

Authors*: Charles J. Ryan, E. David Crawford, Neal D. Shore, Willie Underwood, Mary-Ellen Taplin, Anil Londhe, Peter St. John Francis, Jennifer Phillips, Tracy McGowan, Philip W. Kantoff

Abstract #: 5061





Ryan Research Interests: Dr. Ryan’s clinical practice focuses predominantly on advanced prostate cancer as well as germ cell (testicular) tumors and other malignancies of the genitourinary tract. His clinical and research work centers on the design and conduct of clinical trials of novel therapies for advanced prostate cancer, specifically secondary hormonal therapies targeting adrenal androgen signaling, androgen receptor targeted therapy and chemotherapy. In addition to clinical trials, Dr. Ryan collaborates with many laboratories researching the role of the androgen receptor and other signaling mechanisms in prostate cancer patients.

http://cancer.ucsf.edu/people/profiles/ryan_charles.3649

26

Presentations


Updated results: A phase I/IIa randomized trial of radium-223 + docetaxel versus docetaxel in patients with castration-resistant prostate cancer and bone metastases.

Authors*: Michael J. Morris, Yohann Loriot, Christopher Sweeney, Karim Fizazi, Charles J. Ryan, Daniel H. Shevrin, Emmanuel S. Antonarakis, John Reeves, Kumari Chandrawansa, Martin Kornacker, Celestia S. Higano

Abstract #: 5075







27

Presentations


Immunogenicity of sipuleucel-T (Sip-T) in abiraterone (Abi)/enzalutamide (Enz) sensitive and resistant metastatic castrate-resistant prostate cancer (mCRPC).

Authors*: Eric Jay Small, Lawrence Fong, David I. Quinn, Charles G. Drake, Dwayne Campogan, Tuyen Vu, Nadeem Anwar Sheikh, Nancy N. Chang, Daniel Peter Petrylak

Abstract #: 5077






http://cancer.ucsf.edu/people/profiles/small_eric.3671 __________________________________________________________________________

Preliminary results for the advanced salivary gland carcinoma cohort of the phase 1b KEYNOTE-028 study of pembrolizumab.

Authors*: Roger B. Cohen, Jean-Pierre Delord, Toshihiko Doi, Sarina Anne Piha-Paul, Stephen V. Liu, Jill Gilbert, Alain Patrick Algazi, Sara Cresta, Ruey-Long Hong, Christophe Le Tourneau, Daphne Day, Andrea Varga, Elena Elez, John M. Wallmark, Sanatan Saraf, Anne Morosky, Jonathan D. Cheng, Bhumsuk Keam

Abstract #: 6017



Session: Head and Neck Cancer


28

Presentations


Predicting overall survival (OS) and progression-free (PFS) for oropharynx cancers (OPC) in NRG Oncology RTOG0129/0522 with nomograms.

Authors*: Carole Fakhry, Qiang Zhang, Maura L. Gillison, Phuc Duy Nguyen, David Ira Rosenthal, Randal S. Weber, Louise Lambert, Andy Trotti, William Barrett, Wade Thorstad, Sue S Yom, Stuart J. Wong, John A. Ridge, Shyam S. Rao, James A. Bonner, Eric Vigneault, David Raben, Jonathan Harris, Quynh-Thu Le

Abstract #: 6024





Yom Research Interests: Dr. Yom is an expert in head and neck, thoracic, and skin cancers and conducts research in quality of life and supportive care, patient-oriented decision making, and combinations of novel targeted therapies and immunotherapy with radiation therapy. She is the principal investigator of HN002, a national trial in de-intensified therapy for HPV+ oropharyngeal cancer. She serves on several national panels developing guidelines for appropriate care of head and neck cancers.

http://profiles.ucsf.edu/sue.yom __________________________________________________________________________

The prognostic role of gender, race and human papillomavirus (HPV) in oropharyngeal squamous cell cancer (OPC) and non-oropharyngeal head and neck squamous cell cancer (non-OP HNC).

Authors*: Carole Fakhry, William H. Westra, Steven Wang, Annemieke VanZante, Yuehan Zhang, Eleni Marie Rettig, Alicia Wentz, Young Jun Kim, Justin A. Bishop, Wayne Koch, Christine Gail Gourin, Jeremy Richmon, David Eisele, Gypsyamber D’Souza

Abstract #: 6068





29

Presentations


Pembrolizumab for advanced papillary or follicular thyroid cancer: preliminary results from the phase 1b KEYNOTE-028 study.

Authors*: Janice M. Mehnert, Andrea Varga, Marcia Brose, Rahul Raj Aggarwal, Chia-Chi Lin, Amy Prawira, Filippo de Braud, Kenji Tamura, Toshihiko Doi, Sarina Anne Piha-Paul, Jill Gilbert, Sanatan Saraf, Pradeep Thanigaimani, Jonathan D. Cheng, Bhumsuk Keam

Abstract #: 6091





Impact of industry funding and collaboration in oncology RCTs.

Authors*: Anne Linker, Nitin Roper, Annie Yang, Deborah Korenstein

Abstract #: 6592



Poster Session: Health Services Research and Quality of Care


30

Presentations


KEYNOTE-006 study of pembrolizumab (pembro) versus ipilimumab (ipi) for advanced melanoma: Efficacy by PD-L1 expression and line of therapy.

Authors*: Adil Daud, Christian U. Blank, Caroline Robert, Igor Puzanov, Erika Richtig, Kim Allyson Margolin, Steven O’Day, Marta Nyakas, Jose Lutzky, Ahmad A. Tarhini, Elaine McWhirter, Christian Caglevic, Peter Mohr, Michael Millward, Marcus O. Butler, Honghong Zhou, Kenneth Emancipator, Scot Ebbinghaus, Nageatte Ibrahim, Georgina V. Long

Abstract #: 9513



Poster Session: Melanoma/Skin Cancers


Daud Research Interests: Our group at UCSF is focused on developing new immunotherapy agents and specifically understanding the biology of the immune response to PD-1 in melanoma. We developed IL-12 gene therapy in melanoma and carried out the first in human clinical trial in 2005-2007. Based on this work, IL-12 electroporation is being explored in many cancers as an immune agent and as a combination treatment with PD-1 and other checkpoint inhibitors in melanoma. I have been involved in the development of anti-PD-1 antibodies for melanoma. With my colleagues Michael Rosenblum and Max Krummel at UCSF, we have developed a novel assay that profiles the intra-tumoral microenvironment in depth and can predict non-response to PD-1. We are currently exploring novel strategies for PD-1 non-responsive subsets of melanoma (and potentially other cancers).

http://cancer.ucsf.edu/people/profiles/daud_adil.3622 __________________________________________________________________________

Anti-PD-1 therapy in patients with advanced melanoma and preexisting autoimmune disorders (AD) or major toxicity with ipilimumab (IPI).

Authors*: Alexander M. Menzies, Douglas Buckner Johnson, Sangeetha Ramanujam, Victoria Atkinson, Annie N.M. Wong, John J Park, Jennifer Leigh McQuade, Alexander Noor Shoushtari, Katy K. Tsai, Zeynep Eroglu, Oliver Klein, Jessica Cecile Hassel, Jeffrey Alan Sosman, Alex Guminski, Ryan J. Sullivan, Antoni Ribas, Matteo S. Carlino, Michael A. Davies, Shahneen Kaur Sandhu, Georgina V. Long

Abstract #: 9515



Session: Melanoma/Skin Cancers


31

Presentations


Novel T cell exhaustion marker to predict monotherapy PD-1 compared to combination CTLA-4 and PD-1 response in melanoma.

Authors*: Kimberly Loo, Katy K. Tsai, Mariela Pauli, Priscila Munoz Sandoval, Michael Alvarado, Alain Patrick Algazi, Michael Rosenblum, Adil Daud

Abstract #: 9520






http://cancer.ucsf.edu/people/profiles/daud_adil.3622

32

Presentations


Preliminary results from phase II study of combination treatment with HF10, a replication-competent HSV-1 oncolytic virus, and ipilimumab in patients with stage IIIb, IIIc, or IV unresectable or metastatic melanoma.

Authors*: Robert Hans Ingemar Andtbacka, Merrick I. Ross, Sanjiv S. Agarwala, Matthew H. Taylor, John T. Vetto, Rogerio Izar Neves, Adil Daud, Hung T. Khong, Richard S. Ungerleider, Aislyn Boran, Maki Tanaka, Kenneth F. Grossmann

Abstract #: 9543







33

Presentations


Correlation between metastatic site and response to anti-Programmed Death-1 (PD-1) agents in melanoma.

Authors*: Simone M. Goldinger, Katy K. Tsai, Paul Tumeh, Omid Hamid, Adi Nosrati, Kimberly Loo, Barbara Grimes, Alain Patrick Algazi, Mitchell P. Levesque, Reinhard Dummer, Adil Daud

Abstract #: 9549







34

Presentations


A randomized, phase 3, open-label study of nivolumab versus temozolomide (TMZ) in combination with radiotherapy (RT) in adult patients (pts) with newly diagnosed, O-6-methylguanine DNA methyltransferase (MGMT)-unmethylated glioblastoma (GBM): CheckMate-498.

Authors*: John H. Sampson, Antonio Marcilio Padula Omuro, Matthias Preusser, Michael Lim, Nicholas A. Butowski, Timothy Francis Cloughesy, Lewis C. Strauss, Robert Raymond Latek, Prashni Paliwal, Michael Weller, David A. Reardon

Abstract #: TPS2079


Location: Hall A, Poster Board #265b




https://www.ucsfhealth.org/nicholas.butowski __________________________________________________________________________

Phase 2 study to evaluate the clinical efficacy and safety of MEDI4736 (durvalumab) in patients with glioblastoma (GBM).

Authors*: David A. Reardon, Thomas Joseph Kaley, Jorg Dietrich, Michael Lim, Gavin P Dunn, Hui Kong Gan, Timothy Francis Cloughesy, Jennifer Leigh Clarke, Andrew J. Park, Mary J. Macri, Aileen Ryan, Toni Ricciardi, Vijay Reddy, Ralph Rudolph Venhaus

Abstract #: TPS2080





35

Presentations


ATLAS: A randomized, double-blind, placebo-controlled, phase 3 trial of apalutamide (ARN-509) in patients with high-risk localized or locally advanced prostate cancer receiving primary radiation therapy.

Authors*: Howard M. Sandler, Michael R. McKenzie, Bertrand F. Tombal, Edwina Baskin-Bey, Stephen J. Freedland, Mack Roach, Anders Widmark, Alberto Bossi, Adam Dicker, Thomas Wiegel, Neal D. Shore, Matthew Raymond Smith, Margaret K. Yu, Thian Kheoh, Shibu Thomas, David P. Dearnaley

Abstract #: TPS5087




Citation: J Clin Oncol 34, 2016 (suppl; abstr TPS5087) __________________________________________________________________________

Intense exercise for survival among men with metastatic castrate-resistant prostate cancer (INTERVAL – MCRPC): A Movember funded multicenter, randomized, controlled phase III study.

Authors*: Fred Saad, Stacey A. Kenfield, June M. Chan, Nicolas H. Hart, Kerry S. Courneya, James Catto, Stephen P. Finn, Rosemary Greenwood, Daniel C Hughes, Lorelei A. Mucci, Stephen R Plymate, Michael N. Pollak, Stephan F.E. Praet, Aaron P. Russell, Emer M. Guinan, Erin Van Blarigan, Orla Casey, Mark Buzza, Charles J. Ryan, Robert Usher Newton

Abstract #: TPS5092







36

Presentations


Clinical activity of anti-programmed death-1 (PD-1) agents in acral and mucosal melanoma.

Authors*: Rodrigo Ramella Munhoz, Alexander Noor Shoushtari, Deborah Kuk, Patrick Alexander Ott, Douglas Buckner Johnson, Katy K. Tsai, Suthee Rapisuwon, Zeynep Eroglu, Ryan J. Sullivan, Jason John Luke, Tara C. Gangadhar, April K. Salama, Varina Clark, Clare Burias, Igor Puzanov, Michael B. Atkins, Alain Patrick Algazi, Antoni Ribas, Jedd D. Wolchok, Michael Andrew Postow

Abstract #: 9516





Randomized phase II/III trial of active immunotherapy with OPT-822/OPT-821 in patients with metastatic breast cancer.

Authors*: Chiun-Sheng Huang, Alice L Yu, Ling-Ming Tseng, Louis W. C. Chow, Ming-Feng Hou, Sara A. Hurvitz, Richard B. Schwab, Chi-Huey Wong, James L. Murray, Hsien-Kun Chang, Hong-Tai Chang, Shin-Cheh Chen, Sung-Bae Kim, Youe-Kong Shue, Hope S. Rugo

Abstract #: 1003


Location: Hall D2

Session: Breast Cancer - Triple-Negative/Cytotoxics/Local Therapy




37

Presentations


A prospective analysis of surgery and survival in stage IV breast cancer (TBCRC 013).

Authors*: Tari A. King, Jaclyn Lyman, Mithat Gonen, Sylvia Reyes, Eun-Sil Shelley Hwang, Hope S. Rugo, Minetta C. Liu, Judy Caroline Boughey, Lisa K. Jacobs, Kandace P. McGuire, Anna Maria Storniolo, Claudine Isaacs, Ingrid M. Meszoely, Catherine H. Van Poznak, Gildy Babiera, Larry Norton, Monica Morrow, Antonio C. Wolff, Eric P. Winer, Clifford A. Hudis, Translational Breast Cancer Research Consortium (TBCRC)

Abstract #: 1006


Location: Hall D2





38

Presentations


Genes Versus T-Cells

Authors*: Chloe Evelyn Atreya

Abstract #:

Presentation Date/Time: Saturday, June 4: 1:51-2:03 PM

Location: Hall D1

Poster Discussion Session: Gastrointestinal (Colorectal) Cancer

Citation:

Atreya Research Interests: Dr. Atreya specializes in gastrointestinal cancer, particularly colorectal cancer. Her research focuses on the interplay of tumor genetics and response to therapies for colorectal cancer, with the goal of improving patient outcomes and quality of life by personalizing treatment. Dr. Atreya is the recipient of numerous awards, including the Conquer Cancer Foundation of the American Society of Clinical Oncology Young Investigator Award and Alliance for Clinical Trials in Oncology Foundation Investigator Award. She is the recipient of a National Cancer Institute/National Institutes of Health K08 Career Development Award for Targeting of Aberrant Signaling in Patient-Derived Colorectal Cancer Models. Dr. Atreya is a member of the American Society of Clinical Oncologists, American Association of Cancer Researchers and Alliance for Clinical Trials in Oncology, Gastrointestinal Committee.

http://cancer.ucsf.edu/gi/chloe-atreya __________________________________________________________________________

Developing a Road Map to Guide Immunotherapy

Authors*: Lawrence Fong

Abstract #:


Location: Hall B1

Oral Abstract Session: Developmental Therapeutics - Immunotherapy

Citation:

Fong Research Interests: My lab focuses on how the immune system interacts with cancer as well as exploring tumor immunotherapies in mouse models and in patients. Our primary focus is in cancer immunotherapy. We investigate how immunotherapies such as immune checkpoint inhibitors and cancer vaccines can enhance anti-tumor immunity both systemically and in the tumor microenvironment. Performing neoadjuvant immunotherapy trials, we determine how specific therapies can recruit immune effectors in cancer patients. Moreover, we have studied how clinical responders may differ from clinical non-responders. We are applying unbiased approaches to studying antigen-specific responses that are modulated in these patients and are currently developing biomarkers that may be redictive of clinical efficacy.

http://hemonc.ucsf.edu/fonglab/

39

Presentations


Circulating Biomarkers: Where Are We Now?

Authors*: Terrence W. Friedlander

Abstract #:

Presentation Date/Time: Saturday, June 4: 4:45 - 4:57 Pm

Location: Hall D1

Poster Discussion Session: Genitourinary (Prostate) Cancer

Citation:

Friedlander Research Interests: I am a clinical and translational oncologist specializing in cancers of the genitourinary tract, specifically bladder and prostate cancers. My research is focused on understanding the basic biology of these malignancies and in developing novel therapeutic ways to treat disease. In recent years my works has explored the prognostic and predictive value of circulating tumor cells (CTCs) in these malignancies. In addition to work exploring CTCs as biomarkers of response and resistance, I have investigated the structural and epigenetic state of advanced prostate cancer, and this work has led to a number of grants and publications. Additionally I have a research focus in immunology, particularly in bladder cancer. As a clinical academic oncologist I serve as principal investigator or co-investigator on a number of clinical trials in advanced prostate and bladder cancer, which allows us to recruit patients for much of our biomarker work.

http://cancer.ucsf.edu/people/profiles/friedlander_terence.4963 __________________________________________________________________________

Early Phase Clinical Trials

Authors*: Nicholas A. Butowski

Abstract #:


Location: S102

Poster Discussion Session: Central Nervous System Tumors

Citation:



40

Presentations


Clinical and genomic characterization of metastatic small cell/neuroendocrine prostate cancer (SCNC) and intermediate atypical prostate cancer (IAC): Results from the SU2C/PCF/AARCWest Coast Prostate Cancer Dream Team (WCDT).

Authors*: Eric Jay Small, Rahul Raj Aggarwal, Jiaoti Huang, Artem Sokolov, Li Zhang, Joshi J. Alumkal, Jack Youngren, Charles J. Ryan, Adam Foye, Robert Evan Reiter, Christopher P. Evans, Martin Gleave, Owen Witte, Josh Stuart, Theodore C. Goldstein, George V. Thomas, Lawrence D. True, Himisha Beltran, Mark A. Rubin, Tomasz M. Beer

Abstract #: 5019


Location: Hall D1

Poster Discussion Session: Genitourinary (Prostate) Cancer




41

Presentations


Extended follow-up results of a phase 1B study (BRIM7) of cobimetinib (C ) and vemurafenib (V) in BRAF-mutant melanoma.

Authors*: Adil Daud, Anna C. Pavlick, Antoni Ribas, Rene Gonzalez, Karl D. Lewis, Omid Hamid, Thomas Gajewski, Igor Puzanov, Jessie J. Hsu, Daniel O. Koralek, Nicholas W. Choong, Grant A. McArthur

Abstract #: 9510


Location: E354b

Poster Discussion Session: Melanoma/Skin Cancers




42

Presentations


Derivation and validation of a prediction scale for response to PD-1 monotherapy.

Authors*: Adi Nosrati, Simone M. Goldinger, Katy K. Tsai, Kimberly Loo, Paul Tumeh, Omid Hamid, Alain Patrick Algazi, Mitchell P. Levesque, Reinhard Dummer, Adil Daud

Abstract #: 9514


Location: E354b

Poster Discussion Session: Melanoma/Skin Cancers




43

Presentations


Adjuvant temozolomide for low grade gliomas: Molecular and radiographic correlates of treatment response in a phase II clinical trial.

Authors*: Michael Traut Wahl, Joanna J Phillips, Annette M Molinaro, Yi Lin, Arie Perry, Daphne Haas-Kogan, Joseph F Costello, Manisha Dayal, Nicholas A. Butowski, Jennifer Leigh Clarke, Michael Prados, Mitchel S. Berger, Sarah J. Nelson, Susan Marina Chang

Abstract #: 2002

Presentation Date/Time: Sunday, June 5: 8:00 - 11:00 AM

Location: S100a

Oral Abstract Session: Central Nervous System Tumors




44

Presentations


Impact of primary (1º) tumor location on overall survival (OS) and progression-free survival (PFS) in patients (pts) with metastatic colorectal cancer (mCRC): Analysis of CALGB/SWOG 80405 (Alliance).

Authors*: Alan P. Venook, Donna Niedzwiecki, Federico Innocenti, Briant Fruth, Claire Greene, Bert H. O’Neil, James Edward Shaw, James Norman Atkins, Laura E. Horvath, Blase N. Polite, Jeffrey A. Meyerhardt, Eileen Mary O’Reilly, Richard M. Goldberg, Howard S. Hochster, Charles David Blanke, Richard L. Schilsky, Robert J. Mayer, Monica M. Bertagnolli, Heinz-Josef Lenz

Abstract #: 3504


Location: Hall B1




http://cancer.ucsf.edu/people/profiles/venook_alan.3698 __________________________________________________________________________

The relationship between primary tumor sidedness and prognosis in colorectal cancer.

Authors*: Deborah Schrag, Shicheng Weng, Gabriel Brooks, Jeffrey A. Meyerhardt, Alan P. Venook

Abstract #: 3505


Location: Hall B1





45

Presentations


Ribociclib (LEE011) and letrozole in estrogen receptor-positive (ER+), HER2-negative (HER2–) advanced breast cancer (aBC): Phase Ib safety, preliminary efficacy and molecular analysis.

Authors*: Dejan Juric, Pamela N. Munster, Mario Campone, Roohi Ismail-Khan, Laura García-Estevez, Erika Paige Hamilton, Carlos Becerra, Richard H. De Boer, Rina Hui, Anthony Goncalves, Yingbo Wang, Shyeilla V. Dhuria, Ghulam H. Kalimi, Karen Cristina Rodriguez Lorenc, Ingrid A. Mayer

Abstract #: 568



Session: Breast Cancer - HER2/ER


Munster Research Interests: My clinical research interests are first-in-human early phase clinical trials of novel compounds and alternative strategies for the treatment and prevention of cancer. I have been involved in clinical and translational research in early phase clinical trials since 1998. As the program leader for Development Therapeutics and the PI of a peer-reviewed basic science lab, my main focus is on translating preclinical findings into early-stage clinical trials with extensive PK and integration of PD correlative studies and molecular imaging for patients with advanced stage cancer. My basic research interest is centered on the role of epigenetic modification in therapy resistance in breast cancer and epigenetic priming. In addition to studying basic mechanisms of hormone therapy resistance, we have shown that epigenetic modification plays a crucial role in the hormonal regulation and carcinogenesis of breast cancer.

http://cancer.ucsf.edu/people/profiles/munster_pamela.3449 __________________________________________________________________________

Outcome disparities by age and 21-gene recurrence score (RS) in hormone receptor positive (HR+) breast cancer (BC).

Authors*: Valentina I. Petkov, Dave P. Miller, Nadia Howlader, Nathan Gliner, Will Howe, Nicola C. Schussler, Kathleen Cronin, Frederick L. Baehner, Lynne Penberthy, Steven Shak

Abstract #: 574



Session: Breast Cancer- HER2/ER


46

Presentations


Phase 1 study of CB-839, a small molecule inhibitor of glutaminase (GLS) in combination with paclitaxel (Pac) in patients (pts) with triple negative breast cancer (TNBC).

Authors*: Angela DeMichele, James J. Harding, Melinda L. Telli, Pamela N. Munster, Rana McKay, Othon Iliopoulos, Keith W. Orford, Mark K. Bennett, James Walter Mier, Taofeek Kunle Owonikoko, Manish R. Patel, Richard D. Carvajal, Funda Meric-Bernstam, Jeffrey R. Infante

Abstract #: 1011






http://cancer.ucsf.edu/people/profiles/munster_pamela.3449

47

Presentations


Androgen receptor (AR) expression in primary breast cancer (BC): Correlations with clinical characteristics and outcomes.

Authors*: Neelima Vidula, Christina Yau, Denise M Wolf, Hope S. Rugo

Abstract #: 1072



Poster Session: Breast Cancer - Triple-Negative/Cytotoxics/Local Therapy




48

Presentations


Efficacy of a novel antibody-drug conjugate (ADC), ABT-414, as monotherapy in epidermal growth factor receptor (EGFR) amplified, recurrent glioblastoma (GBM).

Authors*: Martin J. Van Den Bent, Hui Kong Gan, Andrew B. Lassman, Priya Kumthekar, Ryan Merrell, Nicholas A. Butowski, Zarnie Lwin, Tom Mikkelsen, Louis B. Nabors, Kyriakos P. Papadopoulos, Marta Penas-Prado, John Simes, Helen Wheeler, Erica J. Gomez, Ho-Jin Lee, Lisa Roberts-Rapp, Hao Xiong, Earle E. Bain, Kyle D. Holen, David A. Reardon

Abstract #: 2542



Session: Developmental Therapeutics - Clinical Pharmacology and Experimental Therapeutics




49

Presentations


Efficacy and hematologic toxicity of carboplatin and talazoparib combination therapy in BRCA mutated patients.

Authors*: Mallika Sachdev Dhawan, Rahul Raj Aggarwal, Imke Bartelink, Jim Leng, Scott Thomas, Nela Pawlowska, Laurie Stevenson, Amy Jo Chien, Robin Kate Kelley, Julia Clennell, Pamela N. Munster

Abstract #: 2557



Poster Session: Developmental Therapeutics - Clinical Pharmacology and Experimental Therapeutics




50

Presentations


Association between T cell repertoire diversification and both clinical response as well as toxicity following immune checkpoint blockade in metastatic cancer patients.

Authors*: David Yoonsuk Oh, Jason Cham, Li Zhang, Grant Fong, Mark Klinger, Malek Faham, Lawrence Fong

Abstract #: 3029



Post Session: Developmental Therapeutics - Immunotherapy




51

Presentations


IMpassion130: a Phase III randomized trial of atezolizumab with nab-paclitaxel for first-line treatment of patients with metastatic triple-negative breast cancer (mTNBC).

Authors*: Leisha A. Emens, Sylvia Adams, Sherene Loi, Andreas Schneeweiss, Hope S. Rugo, Eric P. Winer, Carlos H. Barrios, Veronique Dieras, Juan de la Haba-Rodriguez, Luca Gianni, Stephen Y. Chui, Peter Schmid

Abstract #: TPS1104







52

Presentations


A randomized, double-blind, placebo-controlled study of ibrutinib, a Bruton tyrosine kinase inhibitor, with nab-paclitaxel and gemcitabine in the first-line treatment of patients with metastatic pancreatic adenocarcinoma (RESOLVE).

Authors*: Margaret A. Tempero, Lisa M Coussens, Lawrence Fong, Robert Manges, Priyanka Singh, Yunfeng Li, George W. Cole, Danelle Frances James, Josep Tabernero

Abstract #: TPS2601



Poster Session: Developmental Therapeutics - Clinical Pharmacology and Experimental Therapeutics


Tempero Research Interests: My research focuses on pancreatic ductal adenocarcinoma, especially in investigational therapeutics. I was a pioneer in the use of mAb-based therapies and helped develop the fixed dose rate concept for gemcitabine. My group developed effective gemcitabine combinations, provided a foundation for using CA19-9 as a clinical surrogate for survival and currently is assessing molecular subtypes and molecular enrichment for selecting new drugs for clinical evaluation. We have a strong emphasis on immunotherapy. I am a SU2C Dream Team member evaluating innovative immunotherapy approaches in this disease. I am also co-PI of a U01 award to establish high risk cohorts for testing candidate early diagnosis biomarkers. I am the UCSF Pancreas Center Director and Pancreas Cancer Program Leader. I have served as the NCCN Guidelines Panel Chair on Pancreatic Cancer since 2000. I serve on SABs to many groups and institutions including the Mayo Clinic Pancreas Cancer SPORE and MDACC’s Moon Shot Program.

http://cancer.ucsf.edu/people/profiles/tempero_margaret.3701

53

Presentations


Randomized phase II trial of a DNA vaccine encoding prostatic acid phosphatase (PAP) versus GM-CSF adjuvant in patients with biochemically recurrent prostate cancer.

Authors*: Glenn Liu, Lawrence Fong, Emmanuel S. Antonarakis, Jens C. Eickhoff, Laura E. Johnson, Douglas G. McNeel

Abstract #: TPS3114



Session: Developmental Therapeutics - Immunotherapy




54

Presentations


SOLAR-1: A phase III study of alpelisib + fulvestrant in men and postmenopausal women with HR+/HER2– advanced breast cancer (BC) progressing on or after prior aromatase inhibitor therapy.

Authors*: Fabrice Andre, Mario Campone, Eva M. Ciruelos, Hiroji Iwata, Sibylle Loibl, Hope S. Rugo, Celine Wilke, David Mills, Marie Chol, Anne-Sophie Longin, Dejan Juric

Abstract #: TPS618







55

Presentations


Phase II trial with tamoxifen in combination with vorinostat and pembrolizumab in estrogen receptor (+) hormone therapy resistant metastatic breast cancer patients (NCT02395627).

Authors*: Manuela Terranova Barberio, Scott Thomas, Amy Jo Chien, Hope S. Rugo, Michelle E. Melisko, Austin Nicholas Angelidakis, Nela Pawlowska, Travis Deal, Pamela N. Munster

Abstract #: TPS620



Poster Session: Breast Cancer - HER2/ER




56

Presentations


A phase 2 randomized, double-blind, placebo-controlled trial of endocrine therapy ± radium-223 dichloride (Ra-223) in HER2- hormone receptor+breast cancer patients with bone metastases.

Authors*: Robert E. Coleman, Rui Li, Amrita G. Sawhney, Oana Petrenciuc, Hope S. Rugo

Abstract #: TPS622







57

Presentations


Academic and Community Cancer Research United (ACCRU) RU011301I: Adjuvant ado-trastuzumab emtansine (T-DM1) for older patients with human epidermal growth factor receptor 2 (HER2)-positive breast cancer.

Authors*: Rachel A. Freedman, Mei-Yin Polley, Amylou C. Dueck, Arti Hurria, Hyman B. Muss, Kathryn Jean Ruddy, Joleen Marie Hubbard, Heshan Liu, Lauren J. Rogak, Ethan M. Basch, Shaker R. Dakhil, Jason D. Huff, Madhuri Bajaj, Mary Wilkinson, Tareq Al Baghadadi, Sam Benjamin, Rex B Mowat, Clifford A. Hudis, Hope S. Rugo, Eric P. Winer

Abstract #: TPS629







58

Presentations


SOPHIA: A phase 3, randomized study of margetuximab (M) plus chemotherapy (CTX) vs trastuzumab (T) plus CTX in the treatment of patients with HER2+ metastatic breast cancer (MBC).

Authors*: Hope S. Rugo, Mark D. Pegram, William John Gradishar, Javier Cortes, Giuseppe Curigliano, Jon M. Wigginton, Robert Joseph Lechleider, Fatima Cardoso

Abstract #: TPS630





Rugo Research Interests: Dr. Rugo, Director of Breast Oncology & Clinical Trials Education, is PI on multiple clinical trials focusing on combining novel targeted therapeutics to improve the treatment of both early & late stage breast cancer (BC). She also works on studies to improve supportive care for early & late stage BC patients, including with UCSFs Advanced Breast Cancer Program. Dr. Rugo has numerous collaborations with large academic medical centers & consortia in order to expand the novel therapies available to patients. She was the director of the 2016 ASCO Breast Cancer Education Committee meeting, is a member of the Alliance & is a founding member of the Breast Cancer Research Consortium where she co-leads the triple negative working group. She is on the novel agents committee for the neoadjuvant multi-center I SPY2 trial. At UCSF, Dr. Rugo runs the Breast Forum, a bimonthly educational session for breast cancer patients, families & friends from throughout the bay area.


59

Presentations


Prevention of everolimus/exemestane (EVE/EXE) stomatitis in postmenopausal (PM) women with hormone receptor-positive (HR+) metastatic breast cancer (MBC) using a dexamethasone-based mouthwash (MW): Results of the SWISH trial.

Authors*: Hope S. Rugo, Lasikas Seneviratne, J. Thaddeus Beck, John A. Glaspy, Julio Antonio Peguero, Timothy J. Pluard, Navneet Dhillon, Leon C. Hwang, Chaitali Singh Nangia, Ingrid A. Mayer, Timothy F. Meiller, Mark Steven Chambers, Ghulam Warsi, Robert William Sweetman, J. Randy Sabo, Jennifer Keating Litton

Abstract #: 525







60

Presentations


Addition of pazopanib (PZ) to endocrine therapy in hormone resistant advanced breast cancer (ABC.)

Authors*: Melanie Catherine Majure, Ariadna Gasol Cudós, Austin Nicholas Angelidakis, Michelle E. Melisko, Ariel R. Karwat, Amy Jo Chien, Andrei Goga, Mark M. Moasser, John W. Park, Amy N. DeLuca, Hope S. Rugo

Abstract #: 560



Poster Session: Breast Cancer- HER2/ER




61

Presentations


A phase 2 randomized, double-blind, placebo-controlled trial of radium-223 dichloride with exemestane and everolimus in patients with HER2-negative hormone receptor-positive breast cancer and bone metastases.

Authors*: Hope S. Rugo, Rui Li, Oana Petrenciuc, Amily Zhang, Robert E. Coleman

Abstract #: TPS621







62

Presentations


Impact of primary (1˚) tumor location on overall survival (OS) and progression-free survival (PFS) in patients (pts) with metastatic colorectal cancer (mCRC): Analysis of CALGB/SWOG 80405 (Alliance).

Authors*: Alan P. Venook, Donna Niedzwiecki, Federico Innocenti, Briant Fruth,Claire Greene, Bert H. O’Neil, James Edward Shaw, James Norman Atkins, Laura E. Horvath, Blase N. Polite, Jeffrey A. Meyerhardt, Eileen Mary O’Reilly, Richard M. Goldberg, Howard S. Hochster, Charles David Blanke, Richard L. Schilsky, Robert J. Mayer, Monica M. Bertagnolli, Heinz-Josef Lenz

Abstract #: 3504

Presentation Date/Time: Sunday, June 5: 8:00 – 11:00AM

Location: Hall B1

Oral Abstract Session: Gastrointestinal (Colorectal) Cancer




63

Presentations


PD-L1 expression, Cancer Genome Atlas (TCGA) subtype, and mutational load as independent predictors of response to atezolizumab (atezo) in metastatic urothelial carcinoma (mUC; IMvigor210).

Authors*: Jonathan E. Rosenberg, Daniel Peter Petrylak, Michiel Simon Van Der Heijden, Andrea Necchi, Peter H. O’Donnell, Yohann Loriot, Margitta Retz, Jose Luis Perez-Gracia, Joaquim Bellmunt, Petros Grivas, Richard Wayne Joseph, Lawrence Fong, Edward E. Kadel, Zachary Boyd, Dorothee Nickles, Garrett Michael Frampton, Richard Bourgon, Priti S. Hegde, Sanjeev Mariathasan, Thomas Powles

Abstract #: 104


Location: Hall D1

Session: Immunotherapy: Now We’re Getting Personal - Using Genomics and Biomarkers to Predict Response




64

Presentations


Pembrolizumab in patients with advanced cervical squamous cell cancer: Preliminary results from the phase Ib KEYNOTE-028 study.

Authors*: Jean-Sebastien Frenel, Christophe Le Tourneau, Bert H. O’Neil, Patrick Alexander Ott, Sarina Anne Piha-Paul, Carlos Alberto Gomez-Roca, Emilie Van Brummelen, Hope S. Rugo, Shari Thomas, Sanatan Saraf, Mei Chen, Andrea Varga

Abstract #: 5515

Presentation Date/Time: Sunday, June 5: 9:45 AM - 12:45 PM

Location: E450ab

Session: Gynecologic Cancer




65

Presentations


The Heart of the Matter

Authors*: Pamela N. Munster

Abstract #:

Presentation Date/Time: Sunday, June 5: 5:21 - 5:33 PM

Location: Hall D2

Poster Discussion Session: Breast Cancer - Triple-Negative/Cytotoxics/Local Therapy

Citation:



66

Presentations


Phase III randomized study of sorafenib plus doxorubicin versus sorafenib in patients with advanced hepatocellular carcinoma (HCC): CALGB 80802 (Alliance).

Authors*: Ghassan K. Abou-Alfa, Donna Niedzwieski, Jennifer J. Knox, Andreas Kaubisch, James Posey, Benjamin R. Tan, Petr Kavan, Rakesh Goel, Philip Edward Lammers, Tanios S. Bekaii-Saab, Vincent Channing Tam, Lakshmi Rajdev, Robin Kate Kelley, Abby B. Siegel, Jennifer Balletti, James J. Harding, Lawrence Howard Schwartz, Richard M. Goldberg, Monica M. Bertagnolli, Alan P. Venook

Abstract #: 4003

Presentation Date/Time: Monday, June 6: 8:00 - 11:00 AM

Location: Hall B1





67

Presentations


4-year results of the ponatinib phase II PACE trial in patients (pts) with heavily pretreated leukemia.

Authors*: Jorge E. Cortes, Javier Pinilla-Ibarz, Philipp D. Le Coutre, Ronald Paquette, Charles Chuah, Franck E. Nicolini, Jane Apperley, Hanna Jean Khoury, Moshe Talpaz, Michele Baccarani, Stephanie Lustgarten, Frank G. Haluska, Francois Guilhot, Michael W.N. Deininger, Andreas Hochhaus, Timothy P Hughes, Neil P. Shah, Hagop M. Kantarjian

Abstract #: 7013

Presentation Date/Time: Monday, June 6: 8:00 - 11:30 Am


Session: Hematologic Malignancies - Leukemia, Myelodysplastic Syndromes, and Allotransplant


Shah Research Interests: The Shah lab is interested in advancing targeted therapeutics for hematologic malignancies through basic studies of in vitro and in vivo model systems to gain a better understanding of the critical vulnerabilities of malignant cells, and through translational/clinical studies of samples obtained from patients participating in early phase monotherapy clinical studies to identify, validate and override mechanisms of resistance to these agents.

http://shah.ucsf.edu/

68

Presentations


Pharmacokinetics and pharmacodynamics of gliteritinib in patients with relapsed or refractory acute myeloid leukemia.

Authors*: Catherine Choy Smith, Mark J. Levis, Mark Robert Litzow, Alexander E. Perl, Jessica K. Altman, Stan Gill, Geoffrey Yuen, Peter Bonate, Takeshi Kadokura, Angela Joubert James, Charles Liu, Itsuro Nagase, Ogert Fisniku, Erkut Bahceci

Abstract #: 7026



Poster Session - Hematologic Malignancies - Leukemia, Myelodysplastic Syndromes, and Allotransplant.


Smith Research Interests: Our laboratory focuses on identification of therapeutic resistance mechanisms and novel treatment strategies for acute myeloid leukemia (AML), particularly AML associated with mutations in Fms-like Tyrosine Kinase-3 (FLT3). FLT3 is the most frequently mutated gene in AML, with constitutively activating FLT3 internal tandem duplication (ITD) mutations conferring a poor prognosis. We employ a prototypical “bedside to bench and back” approach to the problem of cancer drug resistance, founded on the belief that the ultimate pathway to improved cancer therapy begins with translational studies that utilize samples from patients who have undergone therapy in real time. This strategy allows us to interrogate how tumors can evolve under the selective pressure of cancer therapy and allows us to devise ways to circumvent these evolutionary adaptations.

http://cancer.ucsf.edu/people/profiles/smith_catherine.3369

69

Presentations


Impact of landmark responses on 3-year (yr) outcomes with ponatinib in heavily pretreated CP-CML patients (pts).

Authors*: Martin C. Müller, Michele Baccarani, Michael W.N. Deininger, Francois Guilhot, Andreas Hochhaus, Timothy P. Hughes, Neil P. Shah, Moshe Talpaz, Stephanie Lustgarten, Victor M Rivera, Timothy Piers Clackson, Frank G. Haluska, Jorge E. Cortes

Abstract #: 7053



Session: Hematologic Malignancies - Leukemia, Myelodysplastic Syndromes, and Allotransplant



http://shah.ucsf.edu/

70

Presentations


Early molecular response in patients (pts) with chronic myeloid leukemia in chronic phase (CML-CP) treated with dasatinib (DAS) or imatinib (IM) from DASISION.

Authors*: Neil P. Shah, Giuseppe Saglio, Andreas Hochhaus, Robyn Bilmes, Li Li, Jorge E. Cortes

Abstract #: 7055


Location: Hall A, poster Board #47

Poster Session - Hematologic Malignancies - Leukemia, Myelodysplastic Syndromes, and Allotransplant.



http://shah.ucsf.edu/ __________________________________________________________________________

Clinical, biologic, and outcome differences according to MIBG avidity in children with neuroblastoma: A report from the Children’s Oncology Group (COG).

Authors*: Steven G. DuBois, Rajen Mody, Collin Van Ryn, Arlene Naranjo, Susan G. Kreissman, David Baker, Marguerite T Parisi, Barry L. Shulkin, John M. Maris, Vandana Batra, Julie R. Park, Katherine K. Matthay, Gregory A Yanik

Abstract #: 10526



Session: Pediatric Oncology I


71

Presentations


Phase II study of alisertib, irinotecan, and temozolomide in children with relapsed and refractory neuroblastoma: A report from the New Approaches to Neuroblastoma Therapy (NANT) consortium.

Authors*: Steven G. DuBois, Araz Marachelian, Elizabeth Fox, Rachel A. Kudgus, Joel M. Reid, Susan G. Groshen, Jemily Malvar, Rochelle Bagatell, Lars M. Wagner, John M. Maris, Randall Hawkins, Jesse Courtier, Hollie Lai, Fariba Goodarzian, Hiroyuki Shimada, Najee Boucher, Scarlett Czarnecki, Denice D Tsao-Wei, Katherine K. Matthay, Yael P. Mosse

Abstract #: 10556



Poster Session: Pediatric Oncology


Women informed to screen depending on measures of risk (WISDOM): A RCT of personalized vs. annual screening for breast cancer.

Authors*: Sarah Rosenberg-Wohl, Martin Eklund, Jeffrey Tice, Elad Ziv, Celia Kaplan, Laura Van’t Veer, Andrea LaCroix, Lisa Madlensky, Arash Naeim, Neil Wenger, Alexander D. Borowsky, Joshua Fenton, Hoda Anton-Culver, Michael Hogarth, Thomas Cink, Susie Brain, Diane Heditsian, Vivian Lee, Allison S Fiscalini, Laura Esserman

Abstract #: TPS1594



Poster Session: Cancer Prevention, Genetics, and Epidemiology


Esserman Research Interests: Dr. Esserman, surgeon & breast cancer oncology specialist, is the Carol Franc Buck Breast Care Center Director and co-leads the Breast Oncology Program. Her research is on improving healthcare value through integrating translational science, clinical informatics, systems re-engineering & clinical care delivery. In 2005, she received the NCI SPORE Investigator of the Year Award. In 2016 she received the Arbuckle Award from Stanford Graduate School of Business for Excellence in Management & was named to TIME’s 100 most influential people list. She is PI of the I-SPY TRIAL program, now a model for translational research & innovation in clinical trial design. She launched the Athena Breast Health Network to follow women from screening through treatment & outcomes, incorporating the latest in molecular testing & web-based tools. Athena just launched the WISDOM study to compare personalized vs annual breast cancer screening in 100,000 women and to predict who gets what kind of cancer.

http://profiles.ucsf.edu/laura.esserman

72

Presentations


Phase I trial of dual TOR kinase and DNA-PK inhibitor (CC-115) in advanced solid and hematologic cancers.

Authors*: Pamela N. Munster, Amit Mahipal, John J. Nemunaitis, Monica M. Mita, Luis G. Paz-Ares, Christophe Massard, Tom Mikkelsen, Cristina Cruz, Dana E. Rathkopf, George R. Blumenschein, Manuel Hidalgo, David C. Smith, Barbara Eichhorst, Timothy Francis Cloughesy, Brett Garrick, Torsten Trowe, Ellen Filvaroff, Kristen Hege, Johanna C. Bendell

Abstract #: 2505

Presentation Date/Time: Monday, June 6: 8:00 – 11:00AM

Location: E354b

Oral Abstract Session: Developmental Therapeutics - Clinical Pharmacology and Experimental Therapeutics




FGFR pathway genetic aberrations in cholangiocarcinoma: Demographics and experience with targeted therapy.

Authors*: Apurva Jain, Rachna T. Shroff, Robin Kate Kelley, Ahmed Omar Kaseb, Ying Wang, Reham Abdel-Wahab, Daniel H. Ahn, Andrea Grace Bocobo, Funda Meric-Bernstam, Randi Isaacs, Tanios S. Bekaii-Saab, Milind M. Javle

Abstract #: 109


Location: Hall D1

Session: Actionable Mutations Redefined


73

Presentations


Can lay health workers achieve the triple aim? Results from the Engagement of Patients with Advanced Cancer (EPAC) trial.

Authors*: Manali I. Patel, VJ Periyakoil, Kate Bundorf, David Thom, Arnold Milstein, Steven M Asch, James Kahn

Abstract #: 6507

Presentation Date/Time: Monday, June 6: 9:45 AM - 12:45 PM

Location: S100a

Session: Health Services Research and Quality of Care


Phase I investigation of lenalidomide plus rituximab and outcomes of lenalidomide maintenance in recurrent CNS lymphoma.

Authors*: James L. Rubenstein, Eleanor Fraser, Paul Formaker, James Chi-Chiang Lee, Nianhang Chen, Mallory Kock, Wesley Cheung, Xiaomin Wang, Pamela N. Munster, Bertil Damato

Abstract #: 7502


Location: E354b

Oral Abstract Session: Hematologic Malignancies - Lymphoma and Chronic Lymphocytic Leukemia


Rubenstein Research Interests: Our goals are to develop innovative therapies that are based upon the biological properties of cancer, that have both enhanced efficacy as well as less toxicity compared to established interventions. Our major interests are: 1) identification of genetic factors associated with therapeutic resistance; 2) molecular basis of tumor cell tropism within the brain; 3) elucidation of the tumor immune microenvironment. We are simultaneously engaged in leading phase I and II trials , in correlative studies involving novel immunotherapeutic strategies, in the development of novel preclinical models that facilitate both insights into disease mechanisms as well as the testing of novel therapeutic strategies.

https://bms.ucsf.edu/directory/faculty/james-rubenstein-md-phd

74

Presentations


Abexinostat (ABX) as a means to reverse pazopanib (PAZ) resistance: A phase 1 study in advanced solid tumor malignancies.

Authors*: Rahul Raj Aggarwal, Scott Thomas, Jennifer A. Grabowsky, Armand Harb, Jim Leng, Anne Reinert, Ilaria Mastroserio, Thach-Giao Truong, Pamela N. Munster

Abstract #: 2519


Location: Arie Crown Theater

Poster Disussion Session: Developmental Therapeutics—Clinical Pharmacology and Experimental Therapeutics




Risk Reduction Through Lifestyle Modifications

Authors*: Michelle E. Melisko

Abstract #:


Location: S100a

Education Session: Breast Cancer Survivorship: Strategies for Optimal Care

Citation:

75

Presentations


Medical Management of Low-Grade Gliomas

Authors*: Susan Marina Chang

Abstract #:

Presentation Date/Time: Monday, June 6: 11:50 AM - 12:10 PM

Location: S404

Education Session: Treatment of Low-Grade Gliomas in the Era of Genomic Medicine

Citation:



76

Presentations


Programmed death-ligand 1 (PD-L1) characterization of circulating tumor cells (CTCs) in muscle invasive and metastatic bladder cancer patients.

Authors*: Archana Anantharaman, Terence W. Friedlander, David Lu, Rachel Krupa, Gayatri Premasekharan, Jeffrey Hough, Matthew Edwards, Ryon Graf, Adam Jendrisak, Jessica Louw, Lyndsey Dugan, Dena C. Marrinucci, Ryan Vance Dittamore, Pamela Paris

Abstract #: 4527

Presentation Date/Time: Monday, June 6: 1:00 - 4:30 PM


Poster Session: Genitourinary (Nonprostate) Cancer


Paris Research Interests: My background is in biophysical chemistry. My research focuses on biomarker discovery. As a UCSF Prostate SPORE program Research Fellow, I discovered a DNA-based biomarker set to assess risk of recurrence after primary treatment. My landmark paper in the American Journal of Pathology set the stage for the use of formalin-fixed paraffin-embedded (FFPE) prostate cancer tissue with microarrays for copy-number assessment. I was the first to demonstrate FFPE prostate biopsy tissue could be profiled on high-resolution microarrays. As Professor, I work as a translational researcher in prostate cancer, both in solid tumor and circulating biomarkers. I helped move the circulating tumor cell (CTC) field beyond enumeration and was the first to genomically profile prostate cancer CTCs. Recently, I have applied similar approaches to identify clinically relevant bladder cancer biomarkers. My research goal is to identify predictive and prognostic biomarkers to aid in clinical cancer decision-making.

http://urology.ucsf.edu/research/cancer/cancer-research-programs/paris-laboratory

77

Presentations


Prospective evaluation of circulating cell-free DNA sequencing in patients with metastatic renal cell carcinoma treated with pazopanib plus abexinostat.

Authors*: Jim Leng, Armand Harb, Kamran Abri, Ilaria Mastroserio, Anne Reinert, Jennifer A. Grabowsky, Charles J. Ryan, Terence W. Friedlander, Amy M. Lin, Richard Burnham Lanman, Kimberly C. Banks, Rahul Raj Aggarwal, Pamela N. Munster

Abstract #: 4551







78

Presentations


Phase 1 study of CB-839, a small molecule inhibitor of glutaminase (GLS), alone and in combination with everolimus (E) in patients (pts) with renal cell cancer (RCC).

Authors*: Funda Meric-Bernstam, Nizar M. Tannir, James Walter Mier, Angela DeMichele, Melinda L. Telli, Alice C. Fan, Pamela N. Munster, Richard D. Carvajal, Keith W. Orford, Mark K. Bennett, Othon Iliopoulos, Taofeek Kunle Owonikoko, Manish R. Patel, Rana McKay, Jeffrey R. Infante, Martin Henner Voss, James J. Harding

Abstract #: 4568







ADXS11-001 immunotherapy in squamous or non-squamous persistent/recurrent metastatic cervical cancer: Results from stage I of the phase II GOG/NRG0265 study.

Authors*: Warner King Huh, Don S. Dizon, Matthew A. Powell, Charles A. Leath, Lisa Michelle Landrum, Edward Tanner, Robert Higgins, Stefanie M. Ueda, Michael T. McHale, Bradley J. Monk, Carol Aghajanian

Abstract #: 5516





79

Presentations


A phase II randomized, double-blind trial of a polyvalent vaccine-KLH conjugate (NSC 748933 IND# 14384) + OPT-821 versus OPT-821 in patients with epithelial ovarian (EOC), fallopian tube, or peritoneal cancer who are in second or third complete remission.

Authors*: Paul Sabbatini, Lee-may Chen, Joseph A. Lucci, Kian Behbakht, Nicola M. Spirtos, Carolyn Muller, Benedict B. Benigno, Matthew A. Powell, Emily Berry, Krishnansu Sujata Tewari, Parviz Hanjani, Wei Deng, Heather A. Lankes, Carol Aghajanian

Abstract #: 5517





Pembrolizumab in advanced endometrial cancer: Preliminary results from the phase Ib KEYNOTE-028 study.

Authors*: Patrick Alexander Ott, Yung-Jue Bang, Dominique Berton-Rigaud, Elena Elez, Michael J. Pishvaian, Hope S. Rugo, Igor Puzanov, Mark Aloysuis Morgan, Janice M. Mehnert, Kyaw Lwin Aung, Marion Carrigan, Sanatan Saraf, Mei Chen, Jean-Charles Soria

Abstract #: 5581







80

Presentations


Impact of age and comorbidity on treatment of non-small cell lung cancer (NSCLC) recurrence (AFT-03).

Authors*: Melisa L. Wong, Timothy L. McMurry, George J. Stukenborg, Amanda B. Francescatti, Jessica R. Schumacher, Louise C. Walter, Benjamin D. Kozower

Abstract #: 10037



Poster Session: Patient and Survivor Care


Walter Research Interests: Dr. Walter is a clinician-researcher who is a national leader in evaluating the real-world risks and benefits of cancer screening in older patients. Dr. Walter joined the UCSF faculty in July 2001, and she is a geriatrician at the San Francisco VA Medical Center. She has developed novel methodology demonstrating the fundamental importance of life expectancy rather than age in determining benefits and risks of screening. Virtually every cancer screening guideline cites her research. In addition, Dr. Walter led a series of seminal studies demonstrating decisions to screen older adults for cancer are often dictated more by age than health such that many patients in poor health continue to undergo screening while many healthy older patients fail to get screened. Also, she discovered that cancer screening frequently leads to significant harms without benefit in patients in poor health and developed a taxonomy and quantification of screening harms.

http://cancer.ucsf.edu/people/profiles/walter_louise.3728

81

Presentations


Early, molecular detection of cancer utilizing circulating cell-free DNA assay with ultra high accuracy and sensitivity.

Authors*: Stefanie Mortimer, Katharine Dilger, Diana Abdueva, Darya Chudova, Ankit Sarin, Chloe Evelyn Atreya, Jim Leng, Jeeyun Lee, Helmy Eltoukhy, Pamela N. Munster, AmirAli Talasaz

Abstract #: 11540



Poster Session: Tumor Biology


Development and safety of a novel, irreversibly-binding PSMA-targeted prostate cancer radiodiagnostic.

Authors*: Elizabeth Whalley, Clifford Berkman, Henry Vanbrocklin, Beatrice Langton-Webster

Abstract #: 11568



Session: Tumor Biology


VanBrocklin Research Interests: The VanBrocklin laboratory focuses on developing nuclear imaging agents targeting cell surface proteins (receptors, enzymes and transporters) and signalling pathways and mechanisms by PET and SPECT imaging. We have developed imaging agents covering a broad range of molecular motifs from small molecules, antibodies, antibody fragments (e.g., Fabs, scFv, and diabodies), and aptamers, to proteins and peptides. We synthesize, evaluate and validate tracer mechanisms of localization and retention at the target site. We utilize in vitro and in vivo model systems to test the probes and interpret the data collected from these systems to determine their utility for research or as a future diagnostic. We have successfully translated many of these tracers into humans for drug development or evaluation as future diagnostics.

http://cancer.ucsf.edu/people/profiles/vanbrocklin_henry.3696

82

Presentations


Correlation between local 18F-fluorodeoxyglucose PET/CT and T-cell exhaustion for predicting treatment response in patients with advanced melanoma treated with checkpoint inhibitor mono-therapy.

Authors*: Miguel Hernandez Pampaloni, Lorenzo Nardo, Alain Patrick Algazi, Katy K. Tsai, Kimberly Loo, Luca Facchetti, Susana Ortiz-Urda, Adil Daud

Abstract #: 11572






http://cancer.ucsf.edu/people/profiles/daud_adil.3622 __________________________________________________________________________

CHK1 inhibition as a therapeutic approach in KRAS mutated and squamous cell carcinoma NSCLC patients.

Authors*: Daniela Morales-Espinosa, Silvia García-Román, Miguel Angel Molina-Vila, Ana Gimenez Capitan, Jordi Bertran-Alamillo, Pedro Mendez, Santiago Viteri Ramirez, Niki Karachaliou, Rafael Rosell

Abstract #: 11581





83

Presentations


Metastatic melanoma, glioblastoma and high-grade extrapulmonary neuroendocrine carcinomas (NECs) as novel indications for rovalpituzumab tesirine: A delta-like protein 3 (DLL3)-targeted antibody-drug conjugate (ADC).

Authors*: Stanford L. Peng, Laura Saunders, Sheila Bheddah, Sam Williams, Rahul Raj Aggarwal, Jill E. Shea, Eun Y Lee, Jiaoti Huang, Allison J Zemek, Teri A. Longacre, Douglas Wilmot Ball, Courtney L. Scaife, Barry Nelkin, Lowell Brian Anthony, Pamela L. Kunz, Eric Jay Small, Scott Dylla

Abstract #: 11611







84

Presentations


PALOMA-2: Primary results from a phase III trial of palbociclib (P) with letrozole (L) compared with letrozole alone in postmenopausal women with ER+/HER2– advanced breast cancer (ABC).

Authors*: Richard S. Finn, Miguel Martin, Hope S. Rugo, Stephen E. Jones, Seock-Ah Im, Karen A. Gelmon, Nadia Harbeck, Oleg N. Lipatov, Janice Maria Walshe, Stacy L. Moulder, Eric Roland Gauthier, Dongrui (Ray) Lu, Sophia Randolph, Véronique Diéras, Dennis J. Slamon

Abstract #: 507


Location: Hall D1





85

Presentations


Three-year overall survival for patients with advanced melanoma treated with pembrolizumab in KEYNOTE-001.

Authors*: Caroline Robert, Antoni Ribas, Omid Hamid, Adil Daud, Jedd D. Wolchok, Anthony M. Joshua, Wen-Jen Hwu, Jeffrey S. Weber, Tara C. Gangadhar, Richard Wayne Joseph, Roxana Stefania Dronca, Amita Patnaik, Hassane M. Zarour, Richard Kefford, Peter Hersey, Xiaoyun Li, Scott J. Diede, Scot Ebbinghaus, F. Stephen Hodi

Abstract #: 9503







86

Presentations


Pembrolizumab versus ipilimumab for advanced melanoma: Final overall survival analysis of KEYNOTE-006.

Authors*: Jacob Schachter, Antoni Ribas, Georgina V. Long, Ana Arance, Jean Jacques Grob, Laurent Mortier, Adil Daud, Matteo S. Carlino, Catriona M. McNeil, Michal Lotem, James M. G. Larkin, Paul Lorigan, Bart Neyns, Christian U. Blank, Teresa M. Petrella, Omid Hamid, Honghong Zhou, Scot Ebbinghaus, Nageatte Ibrahim, Caroline Robert

Abstract #: 9504







87

Presentations


Heritage: A phase III safety and efficacy trial of the proposed trastuzumab biosimilar Myl-1401O versus herceptin.

Authors*: Hope S. Rugo, Abhijit Barve, Cornelius F. Waller, Miguel Hernandez-Bronchud, Jay Herson, Jinyu Yuan, Alexey Manikhas, Igor Bondarenko, Guzel Mukhametshina, Gia Nemsadze, Joseph D. Parra, Maria Luisa T. Abesamis Tiambeng, Kakhaber Baramidze, Charuwan Akewanlop, Ihor Vynnychenko, Virote Sriuranpong, Gopichand Manillapalli, Sirshendu Ray, Eduardo Patricio Yanez Ruiz, Eduardo J. Pennella

Abstract #: LBA503


Location: Hall D1

Oral Abstract Session: Breast Cancer - HER2/ER

Citation: J Clin Oncol 34, 2016 (suppl; abstr LBA503)


http://cancer.ucsf.edu/people/profiles/rugo_hope.3648 __________________________________________________________________________

Efficacy and safety of programmed death receptor-1 (PD-1) blockade in metastatic uveal melanoma (UM).

Authors*: Katy K. Tsai, Alexander Noor Shoushtari, Rodrigo Ramella Munhoz, Zeynep Eroglu, Josep M. Piulats, Patrick Alexander Ott, Douglas Buckner Johnson, Jimmy Hwang, Adil Daud, Jeffrey Alan Sosman, Richard D. Carvajal, Bartosz Chmielowski, Michael Andrew Postow, Jeffrey S. Weber, Ryan J. Sullivan, Alain Patrick Algazi

Abstract #: 9507

Presentation Date/Time: Monday, June 6: 1:15 – 4:15PM


Oral Abstract Session: Melanoma/Skin Cancers


88

Presentations


Beyond Hormone Therapy for Breast Cancer: Who Needs Targeted Agents?

Authors*: Hope S. Rugo

Abstract #:


Location: Hall D1

Education Session: Targeted Therapies in Hormone Receptor-Positive Breast Cancer

Citation:


http://cancer.ucsf.edu/people/profiles/rugo_hope.3648 __________________________________________________________________________

Emerging Insights Into Molecular Profiling

Authors*: Wolfgang Michael Korn

Abstract #:


Location: S406

Poster Discussion Session: Tumor Biology

Citation:

Korn Research Interests: Dr. Korn is a physician-scientist focused on the science and management of gastrointestinal cancers. Furthermore, he is the leader of the UCSF Molecular Oncology Initiative and founding Chair of the UCSF Molecular Tumor Board. He is principal investigator of clinical trials exploring new treatments for gastrointestinal cancers and conducts molecularly driven, disease-independent basket trials. His laboratory conducts research aimed at developing combination therapies for gastrointestinal cancers, based on the analysis of signal transduction and DNA repair pathways.

http://cancer.ucsf.edu/gi/michael-korn

89

Presentations


Determining barriers to effective data sharing in cancer genomic sequencing initiatives: A Global Alliance for Genomics and Health (GA4GH) survey.

Authors*: Jeremy Howard Lewin, Daniel J Vis, Emile E. Voest, Rachel Liao, Petra M Nederlof, Barbara A. Conley, David B. Solit, Christopher L. Corless, Paulo V Campregher, Vanessa Tyrell, George Chong, Michael Watson, Sun Young Rha, Tim Maughan, Mark Caulfield, Vladimir Lazar, Laura Esserman, Charles L. Sawyers, Lillian L. Siu, Mark Lawler

Abstract #: 11502

Presentation Date/Time: Tuesday, June 7: 8:00 - 11:00 AM

Location: S100a





90

Presentations


A phase Ib dose escalation trial of isatuximab (SAR650984, anti-CD38 mAb) plus lenalidomide and dexamethasone (Len/Dex) in relapsed/refractory multiple myeloma (RRMM): Interim results from two new dose cohorts.

Authors*: Ravi Vij, Nikoletta Lendvai, Thomas G. Martin, Rachid C. Baz, Frank Campana, Florent Mazuir, Eric Charpentier, Don M. Benson

Abstract #: 8009

Presentation Date/Time: Tuesday, June 7: 9:45 - 11:15 AM

Location: E354b

Session: Novel Combination Therapies in Myeloma


Martin Research Interests: A leading expert in hematology-oncology, Dr. Thomas Martin is the associate director of the Myeloma Institute and director of the Unrelated Donor Transplantation Program for adults at UCSF Medical Center. He is also clinical research director of hematologic malignancies, or blood cancers, at the UCSF Helen Diller Family Comprehensive Cancer Center. His research interests include developing treatments for myeloma and leukemia as well as expanding the use of bone marrow transplants. He has a special interest in umbilical cord blood transplants and is involved in efforts to improve the outcomes following unrelated donor transplants.

http://cancer.ucsf.edu/research/multiple-myeloma/mmti/mmti_team#martin

91

Presentations


Controversies in Local Therapy: Surgery and Radiation

Authors*: Laura Esserman

Abstract #:

Presentation Date/Time: Tuesday, June 7: 11:50 AM - 12:10 PM

Location: S406

Education Session: Less is More: A Multidisciplinary Conversation on Treatment Options

Citation:



92

Presentations


ERASE: Elimination of recurring artifacts and stochastic errors: An NGS analysis approach and its application to liquid biopsy samples.

Authors*: Nicholas Kamps-Hughes, Tony Tran, Reynolds Brobey, Robert J. Amato, Ajjai Shivaram Alva, Pamela Paris, Terence W. Friedlander, Gayatri Premasekharan, Cristian Ionescu-Zanetti

Abstract #: e13002

Presentation Date/Time: Publication Only

Location: Publication Only

Session: Publication Only

Citation: J Clin Oncol 34, 2016 (suppl; abstr e13002)

Paris Research Interests: My background is in biophysical chemistry. My research focuses on biomarker discovery. As a UCSF Prostate SPORE program Research Fellow, I discovered a DNA-based biomarker set to assess risk of recurrence after primary treatment. My landmark paper in the American Journal of Pathology set the stage for the use of formalin-fixed paraffin-embedded (FFPE) prostate cancer tissue with microarrays for copy-number assessment. I was the first to demonstrate FFPE prostate biopsy tissue could be profiled on high-resolution microarrays. As Professor, I work as a translational researcher in prostate cancer, both in solid tumor and circulating biomarkers. I helped move the circulating tumor cell (CTC) field beyond enumeration and was the first to genomically profile prostate cancer CTCs. Recently, I have applied similar approaches to identify clinically relevant bladder cancer biomarkers. My research goal is to identify predictive and prognostic biomarkers to aid in clinical cancer decision-making.

http://urology.ucsf.edu/research/cancer/cancer-research-programs/paris-laboratory __________________________________________________________________________

The WISDOM study pilot: Evaluating a preference-tolerant RCT of risk-based vs. annual breast cancer screening.

Authors*: Sarah Theiner, Celia Kaplan, Setareh Sarrafan, Julissa Cabrera, Sarah Dilys Sawyer, April S Liang, Sarah Rosenberg-Wohl, Miya Frick, Emily Claire Wong, Jeffrey Tice, Elad Ziv, Alexander D. Borowsky, Hoda Anton-Culver, Arash Naeim, Andrea LaCroix, Thomas Cink, Laura Esserman, Laura Van’t Veer, Allison S Fiscalini

Abstract #: e13035





93

Presentations


A pharmacodynamic study of pre-prostatectomy buparlisib in men with high-risk, localized prostate cancer.

Authors*: Archana Anantharaman, Hao Gia Nguyen, Matthew R. Cooperberg, Maxwell V. Meng, Peter Carroll, Terence W. Friedlander, Li Zhang, Miles Thomas, Phillip G. Febbo, Felix Yi-Chung Feng, Charles J. Ryan, Won Kim

Abstract #: e14110




Citation: J Clin Oncol 34, 2016 (suppl; abstr e14110) __________________________________________________________________________

Second-line chemotherapy (CTx) outcomes in advanced biliary cancers (ABC): A retrospective multicenter analysis.

Authors*: Laura Williams Goff, Maeve Aine Lowery, Emmet Jordan, Rui Wang, Andrea Grace Bocobo, Joanne F. Chou, Eileen Mary O’Reilly, James J. Harding, Nancy E. Kemeny, Marinela Capanu, Ann C. Griffin, Joseph P. McGuire, Alan P. Venook, Ghassan K. Abou-Alfa, Robin Kate Kelley

Abstract #: e15636





94

Presentations


Next-generation sequencing (NGS) in an advanced hepatocellular carcinoma (HCC) cohort: Analysis of common mutations, clinical covariates, and overall survival (OS).

Authors*: Robin Kate Kelley, Paige M. Bracci, John Dozier Gordan, Kimberley Evason, Nancy M. Joseph, Andrea Grace Bocobo, Blake K. Rosenthal, Hubert J. Stoppler, Halla Sayed Nimeiri, Alan P. Venook

Abstract #: e15641







95

Presentations


Final results of a phase Ib dose-escalation study of PRI-724, a CBP/beta-catenin modulator, plus gemcitabine (GEM) in patients with advanced pancreatic adenocarcinoma (APC) as second-line therapy after FOLFIRINOX or FOLFOX.

Authors*: Andrew H. Ko, E. Gabriela Chiorean, Eunice Lee Kwak, Heinz-Josef Lenz, Paul I. Nadler, Debra L. Wood, Masamoto Fujimori, Tetsuhi Inada, Hiroyuki Kouji, Robert R. McWilliams

Abstract #: e15721






http://cancer.ucsf.edu/people/profiles/ko_andrew.3444 __________________________________________________________________________

Microarray-based tumor ploidy and its association with lymph node involvement in bladder cancer.

Authors*: Karla Lindquist, Thomas Sanford, Maxwell V. Meng, Pamela Paris, Sima P. Porten

Abstract #: e16012





96

Presentations


Treatment patterns for metastatic castration-resistant prostate cancer (mCRPC) in oncology (ONC) urology (URO) practices: Data from the PROCEED registry.

Authors*: Nicholas J. Vogelzang, Andrew J. Armstrong, Celestia S. Higano, A. Oliver Sartor, Christopher Michael Pieczonka, Raoul S. Concepcion, Ronald F. Tutrone, Carl A. Olsson, James L. Bailen, David F. Penson, Nancy N. Chang, Jennifer Susan LIll, Robert Claude Tyler, Matthew R. Cooperberg

Abstract #: e16503





Dehydroepiandrosterone (DHEA) in metastatic castration-resistant prostate cancer (mCRPC): Preliminary results from the SU2C/PCF/AACR West Coast Dream Team (WCDT)

Authors*: Won Kim, Charles J. Ryan, Li Zhang, Jack Youngren, John Wilton, Joshi J. Alumkal, Tomasz M. Beer, Robert Baertsch, Josh Stuart, Kim N. Chi, Martin Gleave, Matthew Rettig, Robert Evan Reiter, Primo Lara, Christopher P. Evans, Eric Jay Small

Abstract #: e16598







97

Presentations


Comparative performance of surveillance mammography and breast MRI in women with a history of breast cancer.

Authors*: Karen Wernli, Laura E Ichikawa, Karla Kerlikowske, Mary Bush, Dianne Johnson, Diana SM Buist, Susan Brandzel, Wendy DeMartini, Louise Henderson, Lariss Nekhlyudov, Tracy Onega, Brian Sprague, Diana Miglioretti

Abstract #: e18051





Kerlikowske Research Interests: My lab focuses on breast imaging and the epidemiology of invasive breast cancer, DCIS and breast density, and risk prediction models for invasive breast cancer. We have developed cohorts of women at risk for invasive breast cancer and DCIS and developed comprehensive databases that include breast imaging, pathologic, clinical, biomarker, and risk factor data, as well as follow-up for subsequent disease and death.

http://cancer.ucsf.edu/people/profiles/kerlikowske_karla.3457

98

Presentations


Enabling a paradigm shift: A preference-tolerant RCT of personalized vs. annual screening for breast cancer.

Authors*: Sarah Rosenberg-Wohl, Prihatha Narasimmaraj, Allison S Fiscalini, Karyn DiGiorgio, Lisa Latts, Marcus Thygeson, Martin Eklund, Jason Connor, Kristine Broglio, Jeffrey Tice, MaryBeth Kramer, Andrea LaCroix, Robert A. Hiatt, Barbara A. Parker, Tracy M. Layton, Laura Esserman

Abstract #: e18281






http://profiles.ucsf.edu/laura.esserman __________________________________________________________________________

Non-invasive detection of crizotinib resistance in ALK-rearranged lung adenocarcinoma directs treatment with next-generation ALK inhibitors.

Authors*: Nnamdi Ihuegbu, Kimberly C. Banks, Stephen R Fairclough, Oliver A. Zill, Darya Chudova, Richard Burnham Lanman, Collin M. Blakely

Abstract #: e20643





99

Presentations


Identification of symptom clusters by occurrence and severity in lung cancer patients receiving chemotherapy.

Authors*: Melisa L. Wong, Bruce A. Cooper, Judy Mastick, Steven M. Paul, Christine Miaskowski

Abstract #: e21657





Circulating tumor DNA sequencing to reveal the genomic complexity of advanced EGFR-mutant lung adenocarcinoma.

Authors*: Collin M. Blakely, Kimberly C. Banks, Richard Burnham Lanman, Jonathan Riess, Philip C. Mack, Trever Grant Bivona

Abstract #: e23079





Bivona Research Interests: Our team uses the tools of precision medicine to improve the molecular diagnosis and targeted therapy of patients with solid cancers, including lung cancer. Our program focuses on identifying and functionally characterizing the molecular drivers of tumor growth in individual patients. We study patient samples and clinical data to identify novel potential drivers of tumor initiation, progression, and therapy resistance. We functionally annotate the putative molecular drivers using an integrated approach of genetic and pharmacologic tools. This precision approach to understanding the molecular pathogenesis of lung cancer (and other cancers) has led to the discovery of new biomarkers and targets that provide rationale for novel clinical trials we are launching to improve patient survival.

http://www.bivonalab.net/

100

Presentations


Functional annotation of cancer driver genes in breast cancer patient-derived xenografts to identify a novel target for PARP inhibitors.

Authors*: Xiaosong Zhang, Meng Li, Olga Momcilovic, Andrew Beardsley, Roman Camarda, Andrei Goga

Abstract #: e23192





Goga Research Interests: Tumor cells are driven to proliferate, alter their metabolism, and deregulate cell death pathways by oncogene over-expression or the loss of tumor-suppressor genes. We seek to understand how oncogenes alter these pathways using cell-based and transgenic animal models. We are especially interested in how the prototypical oncogene Myc acts in diverse tumor types, including amongst the most aggressive breast and liver cancers and lymphomas. Myc has also been postulated to drive a ‘stem cell like’ gene expression pattern which may regulate tumor stem cell function. We seek to elucidate the genes and pathways that are indispensable for Myc function, and thus uncover potential ‘achilles heels’ of tumor cells. Our ultimate goal is to translate our basic discoveries to novel cancer therapeutics.

http://oncogenes.net/Goga_Lab/Home.html

ucsf helen diller family comprehensive...

Documents